RespireRx Pharmaceuticals (RSPI) 10-Q 20 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 13, 2017
Document And Entity Information
Entity Registrant Name	RespireRx Pharmaceuticals Inc.
Entity Central Index Key	849,636
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,632,761
Trading Symbol	RSPI
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 52,223	$ 92,040
Advance payment on research contract	48,912	48,912
Prepaid expenses, including current portion of long-term prepaid insurance of $14,945 at September 30, 2017 and December 31, 2016	60,334	54,724
Total current assets	161,469	195,676
Equipment, net of accumulated depreciation of $20,590 and $15,730 at September 30, 2017 and December 31, 2016, respectively	307	5,167
Long-term prepaid insurance, net of current portion of $14,945 at September 30, 2017 and December 31, 2016	21,795	33,004
Total assets	183,571	233,847
Current liabilities:
Accounts payable and accrued expenses, including 267,635 and $194,066 payable to related parties at September 30, 2017 and December 31, 2016, respectively	2,958,239	2,494,729
Accrued compensation and related expenses	2,757,433	1,944,559
Convertible notes payable, currently due and payable on demand, including accrued interest of $90,667 and $62,616 at September 30, 2017 and December 31, 2016, respectively (of which $82,305, including accrued interest of $21,305 was deemed to be in default at September 30, 2017 and $75,038, including accrued interest of $14,038, was deemed to be in default at December 31, 2016) (Note 4)	366,667	338,616
Note payable to SY Corporation, including accrued interest of $255,243 and $219,362 at September 30, 2017 and December 31, 2016, respectively (payment obligation currently in default – Note 4)	660,616	594,007
Notes payable to officers, including accrued interest of 22,626 and $11,018 as of September 30, 2017 and December 31, 2016, respectively (Note 4)	177,826	166,218
Non-permanent equity (Notes 3 and 6)		185,000
Other short-term notes payable	29,094	4,095
Total current liabilities	6,949,875	5,727,224
Commitments and contingencies (Note 8)
Stockholders’ deficiency: (Note 6)
Series B convertible preferred stock, $0.001 par value; $0.6667 per share liquidation preference; aggregate liquidation preference $25,001; shares authorized: 37,500; shares issued and outstanding: 11; common shares issuable upon conversion at 0.00030 common shares per Series B share	21,703	21,703
Common stock, $0.001 par value; shares authorized: 65,000,000; shares issued and outstanding: 2,586,761 and 2,149,045 at September 30, 2017 and December 31, 2016, respectively (Notes 2 and 6)	2,587	2,149
Additional paid-in capital	154,391,938	151,993,550
Accumulated deficit	(161,182,532)	(157,510,779)
Total stockholders’ deficiency	(6,766,304)	(5,493,377)
Total liabilities and stockholders’ deficiency	$ 183,571	$ 233,847

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Long term prepaid insurance current portion	$ 14,945	$ 14,945
Equipment, accumulated depreciation	20,590	15,730
Long-term prepaid insurance current portion	14,945	14,945
Accounts payable and accrued expenses to related party	267,635	194,066
Accrued interest on note payable to SY corporation	255,243	219,362
Accrued interest on notes payable to officers	$ 22,626	$ 11,018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	2,586,761	2,149,045
Common stock, shares outstanding	2,586,761	2,149,045
Convertible Notes Payable [Member]
Accrued interest	$ 90,667	$ 62,616
Unamortized discount	82,305	75,038
Notes default amount	$ 21,305	$ 14,038
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference, per share	$ 0.6667	$ 0.6667
Preferred stock, liquidation preference value	$ 25,001	$ 25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares issued	11	11
Preferred stock, shares outstanding	11	11
Preferred stock shares issuable upon conversion, per share	$ 0.00030	$ 0.00030

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating expenses:
General and administrative, including $232,401 and $1,059,010 to related parties for the three months ended September 30, 2017 and 2016, respectively, and 1,671,765 and $3,396,376 to related parties for the nine months ended September 30, 2017 and 2016, respectively	$ 356,292	$ 1,349,970	$ 2,264,485	$ 4,272,215
Research and development, including $133,983 and $476,611 to related parties for the three months ended September 30, 2017 and 2016, respectively, and $702,718 and $1,278,044 to related parties for the nine months ended September 30, 2017 and 2016, respectively	236,856	899,543	1,298,866	2,743,599
Total operating expenses	593,148	2,249,513	3,563,351	7,015,814
Loss from operations	(593,148)	(2,249,513)	(3,563,351)	(7,015,814)
Gain from settlement with service providers		1,076		1,076
Fair value of inducement cost to effect exchange of convertible notes for common stock				(188,274)
Interest expense, including $3,992 and $47,057 to related parties for the three months ended September 30, 2017 and 2016, respectively, and $11,688 and $148,046 to related parties for the nine months ended September 30, 2017 and 2016, respectively	(26,354)	(115,847)	(77,674)	(562,053)
Foreign currency transaction gain (loss)	960	(27,518)	(30,728)	(38,937)
Net loss	(618,542)	(2,391,802)	(3,671,753)	(7,804,002)
Adjustments related to Series G 1.5% Convertible Preferred Stock: Dividend on Series G 1.5% Convertible Preferred Stock				(1,165)
Net loss attributable to common stockholders	$ (618,542)	$ (2,391,802)	$ (3,671,753)	$ (7,805,167)
Net loss per common share - basic and diluted	$ (.27)	$ (1.18)	$ (1.62)	$ (4.31)
Weighted average common shares outstanding - basic and diluted	2,333,257	2,018,892	2,261,160	1,810,824

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
General and administrative expense to related parties	$ 232,401	$ 1,059,010	$ 1,671,765	$ 3,396,376
Research and development expenses to related parties	133,983	476,611	702,718	1,278,044
Interest expense to related parties	$ 3,992	$ 47,057	$ 11,688	$ 148,046
Series G 1.5% Convertible Preferred Stock [Member]
Percentage of dividend on convertible preferred stock		1.50%		1.50%

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Series B Convertible Preferred Stock [Member]
Balance beginning		$ 21,703
Balance beginning, shares		37,500
Sale of common stock units in private placement
Sale of common stock units in private placement, shares
Costs incurred in connection with sale of common stock units
Fair value of common stock options issued as compensation
Reclassification of non-permanent equity
Net loss
Balance ending	$ 21,703	$ 21,703	$ 21,703
Balance ending, shares	37,500	37,500	37,500
Common Stock [Member]
Balance beginning		$ 2,149
Balance beginning, shares		2,149,045
Sale of common stock units in private placement		$ 266
Sale of common stock units in private placement, shares		266,000
Costs incurred in connection with sale of common stock units
Fair value of common stock options issued as compensation
Reclassification of non-permanent equity
Shares issued in connection with unit exchanges		$ 172
Shares issued in connection with unit exchanges, shares		171,716
Net loss
Balance ending	$ 2,587	$ 2,587	$ 2,149
Balance ending, shares	2,586,761	2,586,761	2,149,045
Additional Paid-in Capital [Member]
Balance beginning		$ 151,993,550
Sale of common stock units in private placement		475,734
Costs incurred in connection with sale of common stock units		(20,000)
Fair value of common stock options issued as compensation		1,757,826
Reclassification of non-permanent equity		185,000
Shares issued in connection with unit exchanges		(172)
Net loss
Balance ending	$ 154,391,938	154,391,938	$ 151,993,550
Accumulated Deficit [Member]
Balance beginning		(157,510,779)
Sale of common stock units in private placement
Costs incurred in connection with sale of common stock units
Fair value of common stock options issued as compensation
Reclassification of non-permanent equity
Net loss		(3,671,753)
Balance ending	(161,182,532)	(161,182,532)	(157,510,779)
Balance beginning		(5,493,377)
Sale of common stock units in private placement		476,000
Costs incurred in connection with sale of common stock units		(20,000)
Fair value of common stock options issued as compensation		1,757,826
Reclassification of non-permanent equity		185,000
Shares issued in connection with unit exchanges
Net loss	(618,542)	(3,671,753)	(9,229,760)
Balance ending	$ (6,766,304)	$ (6,766,304)	$ (5,493,377)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (3,671,753)	$ (7,804,002)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	4,860	5,215
Amortization of debt discounts (including beneficial conversion feature) related to convertible notes payable		226,433
Write-off of unamortized debt discounts (including beneficial conversion feature) related to exchange of 10% convertible notes payable for common stock		116,499
Fair value of inducement to effect exchange of 10% convertible notes payable for common stock		188,274
Fair value of warrants issued as additional consideration in connection with loans from officers		140,939
Gain from settlements with service providers		(1,076)
Stock-based compensation expense included in - General and administrative expenses	1,150,925	2,821,748
Stock-based compensation expense included in - Research and development expenses	606,901	1,129,526
Foreign currency transaction (gain) loss	30,728	38,937
(Increase) decrease in -
Advance on research contract		(48,912)
Prepaid expenses	5,599	(28,222)
Increase (decrease) in -
Accounts payable and accrued expenses	463,510	997,776
Accrued compensation and related expenses	812,874	927,300
Accrued interest payable	75,540	77,234
Other short term note payable	24,999
Net cash used in operating activities	(495,817)	(1,212,331)
Cash flows from investing activities:
Purchases of equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from sale of common stock units	476,000	309,985
Placement agent fees	(20,000)
Proceeds from warrant exchange transactions		762,240
Proceeds from issuance of notes payable to officers		155,200
Principal paid on other short-term notes payable		(27,442)
Cash payments in lieu of fractional common shares resulting from reverse stock split		(1,298)
Net cash provided by financing activities	456,000	1,198,685
Cash and cash equivalents:
Net increase (decrease)	(39,817)	(13,646)
Balance at beginning of period	92,040	53,199
Balance at end of period	52,223	39,553
Supplemental disclosures of cash flow information:
Interest	2,133	939
Income taxes
Non-cash financing activities:
Dividends on Series G 1.5% Convertible Preferred Stock		1,165
Deferred financing costs charged to additional paid-in capital		3,429
Short-term note payable issued in connection with the procurement of directors and officers insurance		40,016
Stated value of Series G 1.5% Convertible Preferred Stock converted into common stock		259,731
Fair value of common stock issued to service providers		96,250
Fair value of common stock options issued to service provider		31,174
10% convertible notes payable, including accrued interest of $40,983, exchanged for common stock		344,483
Accrual of fees payable to placement agent in connection with the sale of common stock units	20,000
Fair value of common stock warrants issued to placement agent in connection with the sale of common stock units	27,648
Reclassification of non-permanent equity	$ 185,000

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Debt conversion percentage		10.00%
Series G 1.5% Convertible Preferred Stock [Member]
Percentage of dividend on convertible preferred stock		1.50%
Convertible Notes Payable [Member]
Debt conversion percentage		10.00%
Accrued interest		$ 40,983

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The condensed consolidated financial statements of RespireRx Pharmaceuticals Inc. (“RespireRx”) and its wholly-owned subsidiary, Pier Pharmaceuticals, Inc. (“Pier”) (collectively referred to herein as the “Company,” unless the context indicates otherwise), at September 30, 2017 and for the three months and nine months ended September 30, 2017 and 2016, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the condensed consolidated financial position of the Company as of September 30, 2017, the results of its condensed consolidated operations for the three months and nine months ended September 30, 2017 and 2016, and its condensed consolidated cash flows for the nine months ended September 30, 2017 and 2016. Condensed consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The condensed consolidated balance sheet at December 31, 2016 has been derived from the Company’s audited condensed consolidated financial statements at such date. The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the SEC.

Organization and Business

Organization and Business	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	2. Organization and Business Organization RespireRx was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative, proprietary pharmaceutical compounds known as ampakines, which act within the central nervous system for the treatment of neurological and psychiatric disorders. These ampakines act by enhancing the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors. Subsequently, it was determined that these ampakines enhance AMPA receptors within certain brain stem centers that regulate breathing, and as a result, ameliorate the respiratory disorders and distress produced by various drugs, including opioids that interfere with normal neurological functioning. In order to expand its position with respect to respiratory disorders, in August 2012, RespireRx acquired by merger, Pier. Pier was in the process of developing dronabinol, an FDA approved cannabinoid, for the treatment of obstructive sleep apnea. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. While developing potential applications for respiratory disorders, RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders and is considering developing certain indications, pending additional financing and/or strategic relationships. Reverse Stock Split On August 16, 2016, at a special meeting of the stockholders of the Company, the stockholders approved an amendment to the Company’s Second Restated Certificate of Incorporation (i) to effect, at the discretion of the Company’s Board of Directors, a three hundred twenty five-to-one (325-to-1) reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.001 per share, and (ii) to set the number of the Company’s authorized shares of stock at 70,000,000 shares, consisting of 65,000,000 shares designated as common stock, par value $0.001 per share, and 5,000,000 shares designated as preferred stock, par value $0.001 per share. On September 1, 2016, the Company filed a Certificate of Amendment to the Company’s Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the approved amendment. Pursuant to the amendment, an aggregate of 191.068 fractional shares resulting from the reverse stock split were not issued, but were to be paid out in cash (without interest or deduction) in an amount equal to the number of shares exchanged into such fractional share multiplied by the average closing trading price of the Company’s common stock on the OTCQB for the five trading days immediately before the Certificate of Amendment effecting the reverse stock split was filed with the Delaware Secretary of State ($6.7899 per share, on a post reverse stock split basis) for an aggregate of $1,298. All share and per share amounts with respect to common stock presented herein have been retroactively restated to reflect the 325 to 1 reverse stock split as if it had been effected on the first day of the earliest period presented. Certain share amounts have been rounded to whole shares in the process of recording the effect of the reverse stock split. Business Since its formation in 1987, RespireRx has been engaged in the research and clinical development of a class of proprietary compounds known as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors. Several ampakines, in both oral and injectable form, are being developed by the Company for the treatment of a variety of breathing disorders that are regulated by neuronal cells within the pre-Bötzinger complex of the brain stem. In clinical studies, the Company’s two lead ampakines have shown preliminary efficacy in the control of respiratory depression produced by opioids, without altering their analgesic effects. In animal models of orphan disorders, such as Pompe Disease, spinal cord damage and perinatal respiratory distress, it has been demonstrated that certain ampakines improve breathing function. The Company’s compounds belong to a new class of ampakines that do not display the undesirable side effects of earlier generations of compounds previously reported in animal models. The Company owns patents and patent applications, or the rights thereto, for certain families of chemical compounds, including ampakines, which claim the chemical structures, their actions as ampakines and their use in the treatment of various disorders. Patents claiming a family of chemical structures, including CX1739 and CX1942, as well as their use in the treatment of various disorders, extend through at least 2028. Additional patents claiming a family of chemical structures, including CX717, expired in the U.S in 2017. Method of use patents for CX717 inclusive of a 960 day patent term extension expire in 2030. The Company owns and has licensed patents and patent applications for the classes of drugs known as ampakines and cannabinoids, including dronabinol, claiming a number of medical uses. In 2011, RespireRx conducted a re-evaluation of its strategic focus and determined that clinical development in the area of respiratory disorders, particularly sleep apnea and drug-induced respiratory depression, provided the most cost-effective opportunities for potential rapid development and commercialization of RespireRx’s compounds. Accordingly, RespireRx narrowed its clinical focus at that time and sidelined other avenues of scientific inquiry. This re-evaluation provided the impetus for RespireRx’s acquisition of Pier in August 2012, as described below. The Company has continued to implement this strategic focus, notwithstanding a change in management in March 2013, and has continued its efforts to obtain the capital necessary to fund the clinical activities. As a result of the Company’s scientific discoveries and the acquisition of strategic, exclusive license agreements, management believes that the Company is now a leader in developing drugs for neurologically controlled respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. On May 8, 2007, RespireRx entered into a license agreement, as subsequently amended, with the University of Alberta granting RespireRx exclusive rights to method of treatment patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. These patents, along with RespireRx’s own patents claiming chemical structures, comprise RespireRx’s principal intellectual property supporting RespireRx’s research and clinical development program in the use of ampakines for the treatment of neurologically controlled respiratory disorders. RespireRx has completed pre-clinical studies indicating that several of its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids, sedatives or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. In two clinical Phase 2 studies, one of which was published in a peer-reviewed journal, CX717, a predecessor compound to CX1739 and CX1942, antagonized the respiratory depression produced by alfentanyl, a potent narcotic, without affecting the analgesia produced by this drug. Positive results also were obtained using CX1739 in a Phase 2A study. In addition, RespireRx conducted a Phase 2A clinical study in which patients with sleep apnea were administered CX1739, RespireRx’s lead clinical ampakine compound. The results suggested that CX1739 might have use as a treatment for central sleep apnea (“CSA”) and mixed sleep apnea, but not obstructive sleep apnea (“OSA”). In order to expand RespireRx’s respiratory disorders program, RespireRx acquired by merger, 100% of the issued and outstanding equity securities of Pier effective August 10, 2012 pursuant to an Agreement and Plan of Merger. Pier was formed in June 2007 (under the name SteadySleep Rx Co.) as a clinical stage pharmaceutical company to develop a pharmacologic treatment for OSA and had been engaged in research and clinical development activities. Through the merger, RespireRx gained access to an Exclusive License Agreement (as amended, the “Old License Agreement”) that Pier had entered into with the University of Illinois on October 10, 2007. The Old License Agreement covered certain patents and patent applications in the United States and other countries claiming the use of certain compounds referred to as cannabinoids, of which dronabinol is a specific example, for the treatment of sleep-related breathing disorders (including sleep apnea). Dronabinol is a synthetic derivative of the naturally occurring substance in the cannabis plant, otherwise known as Δ9-THC (Δ9-tetrahydrocannabinol). Pier’s business plan was to determine whether dronabinol would significantly improve subjective and objective clinical measures in patients with OSA. In addition, Pier intended to evaluate the feasibility and comparative efficacy of a proprietary formulation of dronabinol. Dronabinol is a Schedule III controlled drug, available in branded and generic forms, which has a relatively low abuse potential and is approved by the U.S. Food and Drug Administration (the “FDA”) for the treatment of AIDS-related anorexia and chemotherapy-induced nausea and vomiting. The use of dronabinol for the treatment of OSA is a novel indication for an already approved drug and, as such, the Company believes that it would only require approval by the FDA of an SNDA or a 505(b)(2) application, as opposed to the submission and approval of a full new drug application. The Old License Agreement was terminated effective March 21, 2013, due to the Company’s failure to make a required payment. Subsequently, current management opened negotiations with the University of Illinois, and as a result, the Company entered into a new license agreement (the “2014 License Agreement”) with the University of Illinois on June 27, 2014, the material terms of which were similar to the previous Old License Agreement. The 2014 License Agreement grants the Company, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the 2014 License Agreement, that are held by the University of Illinois; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the 2014 License Agreement, subject to the provisions of the 2014 License Agreement. The Company is required under the 2014 License Agreement, among other terms and conditions, to pay the University of Illinois a license fee, royalties, patent costs and certain milestone payments. Prior to the Company’s merger with Pier, Pier conducted a 21 day, randomized, double-blind, placebo-controlled, dose escalation Phase 2A clinical study in 22 patients with OSA, in which dronabinol produced a statistically significant reduction in the Apnea-Hypopnea Index (“AHI”), the primary therapeutic end-point, and was observed to be safe and well tolerated. The results of the Phase 2A study have been published in two peer-reviewed journal articles. On June 6, 2017, at SLEEP 2017, the 31st Annual Meeting of the Associated Professional Sleep Societies, Drs. David Carlee and Phyllis Zee, from the University of Illinois Chicago and Northwestern University, respectively, reported the results of the Phase 2B PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) clinical trial. In this randomized, blinded, placebo controlled study in 73 patients with OSA, dronabinol doses of 2.5 and 5 mg significantly improved the primary outcome measures of AHI, daytime sleepiness as measured by the Epworth Sleepiness Scale (“ESS”) and overall patient satisfaction as measured by the Treatment Satisfaction Questionnaire for Medications (“TSQM”). In comparison to placebo and in a dose-related fashion, dronabinol was associated with lower AHI, improved subjective sleepiness and greater overall treatment satisfaction. Dronabinol was observed to be safe and well tolerated. The number and severity of adverse events produced by dronabinol did not differ from those produced by placebo. The PACE trial was funded by a grant from the NIH of approximately $5 million. The Company did not conduct or fund the PACE trial. The results of this Phase 2B study, substantially replicated the results of the earlier Phase 2A study. While developing potential applications for respiratory disorders, RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders and is considering developing certain indications, pending additional financing and/or strategic relationships. As an example, based on positive results from a Phase 2 clinical trial, RespireRx has filed patent applications for the use of ampakines for the treatment of Attention Deficit Hyperactivity Syndrome (ADHD). In addition, animal studies conducted in collaboration with Dr. David Fuller and his colleagues at the University of Florida have demonstrated the ability of our lead ampakines to significantly enhance the activity of motor nerves, including those innervating the diaphragm, and to improve breathing in animals with spinal cord injury. The Company believes that these results reflect a more general process whereby the ampakines might improve the motor nerve activity of a number of systems. While additional animal studies are planned at the University of Florida, the Company is also planning, pending additional financing, to conduct a Phase 2 clinical trial investigating the ability of our lead ampakines to improve breathing and motor function in spinal cord injury patients. Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $3,671,753 for the nine months ended September 30, 2017 and $9,229,760 for the fiscal year ended December 31, 2016, and negative operating cash flows of $495,817 for the nine months ended September 30, 2017 and $1,328,684 for the fiscal year ended December 31, 2016. The Company also had a stockholders’ deficiency of $6,766,304 at September 30, 2017, and expects to continue to incur net losses and negative operating cash flows for at least the next few years. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2016, has expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has limited cash resources and current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has continued to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties, as described at Notes 6 and 7. The Company is continuing efforts to raise additional capital in order to pay its liabilities, fund its business activities and underwrite its research and development programs. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including the development of agreements with collaborative partners and, when necessary, the exchange or restructuring of the Company’s outstanding securities. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources on a timely basis, the Company may be forced to reduce or suspend operations indefinitely or to discontinue operations entirely and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents. Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms. Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed debt financings are presented as a direct deduction from the carrying amount of the related debt liability (see “Capitalized Financing Costs” below). Costs related to completed equity financings are charged directly to additional paid-in capital. Capitalized Financing Costs The Company presents debt issuance costs related to a debt liability in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the presentation for debt discounts. As of September 30, 2017 and December 31, 2016, the Company did not have any such capitalized financing costs on its condensed consolidated balance sheets. Series G 1.5% Convertible Preferred Stock The shares of Series G 1.5% Convertible Preferred Stock (including accrued dividends) issued in 2014 were mandatorily convertible into common stock at a fixed conversion rate on April 17, 2016 (if not converted earlier) and provided no right to receive a cash payment. Additionally, the Series G 1.5% Convertible Preferred Stock included no participatory or reset rights, or other protections (other than normal anti-dilution rights) based on subsequent events, including equity transactions. Accordingly, the Company categorized the Series G 1.5% Convertible Preferred Stock in stockholders’ deficiency, as there were no derivatives embedded in such security that would require identification, bifurcation and valuation. The Company did not issue any warrants to investors in conjunction with the Series G 1.5% Convertible Preferred Stock financing. Convertible Notes Payable Original Issuance of Notes and Warrants The convertible notes sold to investors in 2014 and 2015 had a fixed interest rate of 10% per annum and are convertible into common stock at a fixed price of $11.3750 per share. The convertible notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The warrants issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share, provided no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. On November 5, 2014, the Company sold an aggregate principal amount of $238,500 of its convertible notes payable due September 15, 2015, which were subject to extension to September 15, 2016, at the option of the Company, subject to the issuance of additional warrants, and warrants to purchase shares of common stock exercisable into a fixed number of shares of common stock of the Company calculated as the principal amount of each convertible note divided by $11.3750 (reflecting 100% warrant coverage). The warrants did not have any cashless exercise provisions and, when issued, were exercisable through September 30, 2015 at a fixed price of $11.3750 per share. The shares of common stock issuable upon conversion of the notes payable and the exercise of the warrants were not subject to any registration rights. In the same offering, on December 9, 2014, December 31, 2014, and February 2, 2015, the Company sold an additional $46,000, $85,000 and $210,000, respectively, of principal amount of the convertible notes and warrants to various accredited investors. The Company terminated this financing effective February 18, 2015, which had generated aggregate gross proceeds of $579,500, and in connection with which the Company had issued warrants to purchase 50,945 shares of common stock. The closing market prices of the Company’s common stock on the transaction closing dates of November 5, 2014, December 9, 2014, December 31, 2014 and February 2, 2015 were $17.0300 per share, $13.3575 per share, $14.6575 per share and $13.9750 per share, respectively, as compared to the fixed conversion price of the convertible notes and the fixed exercise price of the warrants of $11.3750 per share. Accordingly, the Company has accounted for the beneficial conversion features with respect to the sale of the convertible notes and the issuance of the warrants in accordance with Accounting Standards Codification Topic (ASC) 470-20, Accounting for Debt with Conversion and Other Options. The Company considered the face value of the convertible notes to be representative of their fair value. The Company determined the fair value of the warrants based on the Black-Scholes option-pricing model. The relative fair value method generated respective fair values for each of the convertible notes and the warrants of approximately 50% for the convertible notes and approximately 50% for the warrants sold with the convertible notes. Once these values were determined, the fair value of the warrants of $289,106 and the fair value of the beneficial conversion feature of $290,394 (which were calculated based on the effective conversion price) were recorded as a reduction to the face value of the promissory note obligation. As a result, this aggregate debt discount reduced the carrying value of the convertible notes to zero at each issuance date. The excess amount generated from this calculation was not recorded, as the carrying value of a promissory note cannot be reduced below zero. The aggregate debt discount was amortized as interest expense over the original term of the promissory notes. The difference between the amortization of the debt discount calculated based on the straight-line method and the effective yield method was not material. The cash fees paid to placement agents and for legal costs incurred from November 5, 2014 through February 2, 2015 with respect to this financing were deferred and capitalized as deferred offering costs and were amortized to interest expense over the original term of the convertible notes through September 15, 2015 on the straight-line method. The placement agent warrants were considered as an additional cost of the offering and were included in deferred offering costs at fair value. The difference between the amortization of the deferred offering costs calculated based on the straight-line method and the effective yield method was not material. Extension of Notes and Original Warrants, and Issuance of New Warrants On August 13, 2015, pursuant to the terms of the convertible notes, the Company elected to extend the maturity date of the convertible notes to September 15, 2016. Under the terms of the convertible notes, the Company was required to issue to note holders 27,396 additional warrants (the “New Warrants”) that were exercisable through September 15, 2016. The New Warrants were exercisable for that number of shares of common stock of the Company calculated as the principal amount of the convertible notes (an aggregate amount of $579,500), plus any accrued and unpaid interest (an aggregate amount of $43,758), multiplied by 50%, and then divided by $11.3750. The New Warrants otherwise had terms substantially similar to the 50,945 original warrants issued to the investors. In connection with the extension of the maturity date of the convertible notes, the Board of Directors of the Company also determined to extend the termination date of the 50,945 original warrants to September 15, 2016, so that they were coterminous with the new maturity date of the convertible notes. The Company reviewed the guidance in ASC 405-20, Extinguishment of Liabilities, and determined that the convertible notes had not been extinguished. The Company therefore concluded that the guidance in ASC 470-50, Modifications and Extinguishments, should be applied, which states that if the exchange or modification is not to be accounted for in the same manner as a debt extinguishment, then the fees shall be associated with the replacement or modified debt instrument and, along with any existing unamortized premium or discount, amortized as an adjustment of interest expense over the remaining term of the replacement or modified debt instrument using the interest method. The Company deferred the debt modification costs related to the modification of the convertible notes and the issuance of the New Warrants (consisting of the fair value of the New Warrants) over the remaining term of the extended notes. The Company accounted for such costs as a discount to the convertible notes and amortized such costs to interest expense over the extended term of the convertible notes on the straight-line method. The difference between the amortization of these costs calculated based on the straight-line method and the effective yield method was not material. The Company deferred the debt modification costs related to the extension of the original warrants (consisting of the fair value of the extension of the original warrants) over the remaining term of the extended convertible notes. The Company accounted for such costs as a discount to the convertible notes and amortized such costs to interest expense over the extended term of the convertible notes on the straight-line method. The difference between the amortization of these costs calculated based on the straight-line method and the effective yield method was not material. The closing market price of the Company’s common stock on the extension date of September 15, 2015 was $10.0750 per share, as compared to the fixed conversion price of the convertible notes and the fixed exercise price of both the original warrants and the New Warrants of $11.3750 per share. The Company accounted for the beneficial conversion features with respect to the extension of the convertible notes and the extension of the original warrants and the issuance of the New Warrants in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company considered the face value of the convertible notes, plus the accrued interest thereon, to be representative of their fair value. The Company determined the fair value of the 27,396 New Warrants and the fair value of extending the 50,945 original warrants based on the Black-Scholes option-pricing model. The relative fair value method generated respective fair values for each of the convertible notes, including accrued interest, and the New Warrants and extension of the original warrants, of approximately 55% for the convertible notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original warrants. Once these values were determined, the fair value of the New Warrants and extension of the original warrants of $277,918 and the fair value of the beneficial conversion feature of $206,689 (which were calculated based on the effective conversion price) were recorded as a reduction to the face value of the promissory note obligation. The aggregate debt discount was amortized as interest expense over the extended term of the promissory notes. The difference between the amortization of the debt discount calculated based on the straight-line method and the effective yield method was not material. Note Exchange Agreements During April and May 2016, the Company entered into Note Exchange Agreements with certain note holders, including one non-officer/director affiliate, as described below, representing an aggregate of $303,500 of principal amount of the convertible notes (out of a total of $579,500 of original principal amount of the convertible notes payable). The Note Exchange Agreements were substantially similar, and provided for the note holders to exchange their notes, original warrants and New Warrants (collectively, the “Exchanged Securities”), plus cash, in exchange for shares of the Company’s common stock. In the aggregate, $344,483 of principal amount and accrued interest of the convertible notes, original warrants to purchase 26,681 shares of the Company’s common stock and New Warrants to purchase 14,259 shares of the Company’s common stock, plus an aggregate of $232,846 in cash, were exchanged for 101,508 shares of the Company’s common stock, with a total market value of $631,023 (average $6.2075 per share), which resulted in a credit to total stockholders’ deficiency of $577,329. All of the Exchanged Securities were cancelled as a result of the respective exchange transactions. Among the executed Note Exchange Agreements, the Company entered into one Note Exchange Agreement with a non-officer/director affiliate effective May 4, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which this affiliate exchanged $28,498 of principal amount and accrued interest of the convertible notes, original warrants to purchase 2,198 shares of the Company’s common stock and New Warrants to purchase 1,178 shares of the Company’s common stock, plus $19,200 in cash, in return for 8,386 shares of the Company’s common stock. This transaction was treated as though the exchanging note holders agreed to exchange their convertible notes (including accrued interest) into common stock at a 50% discount to the conversion rate ($11.3750 per share) provided for by the terms of the convertible notes, if they also exchanged all of their warrants associated with the convertible notes, plus paid cash equal to a 50% discount to the exercise price ($11.3750 per share). For accounting purposes, the transactions have been treated as if (i) the participants had converted the convertible notes (which included accrued but unpaid interest of $40,993) at a conversion price reduced from $11.3750 to $5.6875 per share, and that such conversions in the aggregate resulted in the issuance of an aggregate of 60,568 shares of common stock, and (ii) the participants had exercised their original warrants to purchase an aggregate of 26,681 shares of common stock and the New Warrants to purchase an aggregate of 14,259 shares of common stock, all at an exercise price reduced from $11.3750 to $5.6875 per share, and that such exercise of the warrants generated an aggregate cash payment to the Company of $232,846 and resulted in the issuance of an aggregate of 40,940 shares of common stock. In connection with the exchange of the convertible notes, original warrants, New Warrants and the payment of cash, a total of 101,508 shares of common stock in the aggregate were issued. The closing market price of the Company’s common stock during the period that these exchange transactions were entered into ranged from $5.8500 to $7.7675 per share. The Company reviewed the guidance in ASC 470-20-40-13 through 17, Recognition of Expense Upon Conversion, and in ASC 470-20-40-26, Induced Conversions. Pursuant to this accounting guidance, for those convertible note holders accepting the Company’s exchange offer, the Company evaluated the fair value of the incremental consideration paid to induce the convertible note holders to exchange their convertible notes for equity (i.e., 30,284 shares of common stock), based on the closing market price of the Company’s common stock on the date of each transaction, and recorded a charge to operations of $188,274. The Company evaluated the warrants exchanged in conjunction with the Note Exchange Agreements. The Company calculated the fair value of the warrants exchanged (consisting of the warrants issued in conjunction with the original issuance of the convertible notes) as if the warrants were modified immediately before the theoretical warrant modification and immediately after such warrant modification. As the fair value of the warrants immediately after the modifications was less than the fair value of the warrants immediately before the modifications (both amounts calculated pursuant to the Black-Scholes option-pricing model), the Company did not record any accounting entry with respect to the warrant exchange transactions. The fair value of the warrants subject to the Note Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 11.3750 $ 5.6875 Stock price $5.8500 to $7.5400 $5.8500 to $7.5400 Risk-free interest rate 0.23 % 0.23 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 months 0 months 2015 Unit Offering Units sold to investors on August 28, 2015, September 28, 2015 and November 2, 2015 were comprised of one share of the Company’s common stock and one common stock purchase warrant to purchase two additional shares of the Company’s common stock. Units were sold for $6.83475 per unit and the warrants issued in connection with the units were exercisable at a fixed price $6.83475 per share of the Company’s common stock. The warrants provided no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this unit financing. The aggregate gross proceeds of this unit financing was $1,194,710. Unit Exchange Agreements During April and May 2016, the Company entered into Unit Exchange Agreements with certain warrant holders, including two affiliates, one of whom was Dr. Manuso, and the other of whom was a non-officer/director affiliate, both as described below. The Unit Exchange Agreements were substantially similar, and provided for the warrant holders to exchange (i) existing warrants to purchase an aggregate of 217,188 shares of the Company’s common stock (which were cancelled as a result of the respective exchange transactions), plus (ii) an aggregate of $529,394 in cash, in return for (i) an aggregate of 108,594 shares of the Company’s common stock, and (ii) new warrants to purchase an aggregate of 108,594 shares of the Company’s common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. Among the executed Unit Exchange Agreements, the Company entered into a Unit Exchange Agreement with Dr. Manuso effective April 6, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which Dr. Manuso exchanged a warrant to purchase 73,156 shares of the Company’s common stock that was originally issued to him in the Company’s August 28, 2015 unit offering (which was cancelled as a result of the exchange transaction), plus $178,317 in cash, in return for 36,578 shares of the Company’s common stock and the issuance of a new warrant to purchase 36,578 shares of the Company’s common stock. The new warrant has the same expiration date as the original warrant (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. The closing market price of the Company’s common stock on April 6, 2016 was $7.7675 per share. Among the executed Unit Exchange Agreements, the Company also entered into Unit Exchange Agreements (which are included in the summary paragraph above) with a non-officer/director affiliate (and his affiliate) effective May 4, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which this affiliate exchanged warrants to purchase 88,132 shares of the Company’s common stock that were originally issued to the affiliate in the Company’s August 28, 2015 unit offering (which were cancelled as a result of the exchange transaction), plus $214,822 in cash, in return for 44,066 shares of the Company’s common stock and the issuance of new warrants to purchase 44,066 shares of the Company’s common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. The closing market price of the Company’s common stock on May 4, 2016 was $5.8500 per share. This transaction was treated as though exchanging warrant holders who received their warrants in any of the three closings of the Company’s 2015 unit offering agreed to exchange their warrants associated with such financing, plus paid cash equal to a reduced exercise price per share ($4.8750 per share) for 50% of such warrants, with 50% of the warrants replaced with similar warrants with the same term at a reduced exercise price. For accounting purposes, the transactions have been treated as if (i) participants exercised one-half of the existing warrants entitling them to purchase an aggregate of 217,188 shares of the Company’s common stock that were originally issued to them in the Company’s unit offering, with closings on August 28, 2015, September 28, 2015 and November 2, 2015 (i.e., warrants to purchase 108,594 shares of common stock), at an exercise price reduced from $6.8348 to $4.8750 per share, and (ii) the other one-half of the original warrants were cancelled. The Unit Exchange Agreements also provided for the Company to issue new warrants to the participants to purchase an aggregate of 108,594 shares of common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. For accounting purposes, the transaction was treated as if the warrant exercise price for all of the warrants was reduced from $6.8348 to $4.8750 per share, in exchange for which 50% of the warrants were exercised for cash at the reduced exercise price, and the remaining 50% of the warrants continued to remain outstanding through September 30, 2020 and gained a cashless exercise provision. The closing market price of the Company’s common stock during the period that these exchange transactions were entered into ranged from $5.8500 to $7.7675 per share. The Company evaluated the warrants exchanged in conjunction with the Unit Exchange Agreements. The Company calculated the fair value of the warrants exchanged as if the warrants were modified immediately before the theoretical warrant modification and immediately after such warrant modification. As the fair value of the warrants immediately after the modifications was less than the fair value of the warrants immediately before the modifications (both amounts calculated pursuant to the Black-Scholes option-pricing model), the Company did not record any accounting entry with respect to the warrant exchange transactions. The fair value of the warrants subject to the Unit Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 6.8348 $ 4.8750 Stock price $5.8500 to $7.7675 $5.8500 to $7.7675 Risk-free interest rate 1.12 % 0.23 % and 1.12 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 years 0 years to 4.5 years 1 st Units were sold to investors from January 8, 2016 through June 30, 2016 (the “1 st The closing market prices of the Company’s common stock on the transaction closing dates from January 8, 2016 through June 30, 2016, ranged from a low of $3.4416 on February 9, 2016 to a high of $9.7403 on February 29, 2016. 2 nd On December 29, 2016 and December 30, 2016, the Company sold units to investors for aggregate gross proceeds of $185,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (the “2 nd nd nd The closing market prices of the Company’s common stock on December 29, 2016 and December 30, 2016 were $2.85 and $2.80 respectively. 1 st On March 10, 2017 and March 28, 2017, the Company sold units to investors for aggregate gross proceeds of $350,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (the “1 st nd st On July 26, 2017, the Company’s Board approved an offering of securities conducted via private placement (the “2 nd nd st st nd st nd nd 2 nd On August 29, 2017, September 27, 2017, September 28, 2017, October 5, 2017 and October 25, 2017, the Company sold units to investors for aggregate gross proceeds of $157,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (2 nd nd nd nd The terms of the 2 nd st st nd nd Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. Long-Term Prepaid Insurance Long-term prepaid insurance represents the premium paid in June 2017 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve-month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2017. Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company’s financial statements ratably over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Board members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Board and to outside consultants are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, the risk-free interest rate and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Comp

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable Convertible Notes Payable On November 5, 2014, the Company entered into a Convertible Note and Warrant Purchase Agreement (the “Purchase Agreement”) with various accredited, non-affiliated investors (each, a “Purchaser”), pursuant to which the Company sold an aggregate principal amount of $238,500 of its (i) Convertible Notes due September 15, 2015 (each a “Note”, and together, the “Notes”) and (ii) Warrants to purchase shares of common stock (the “Warrants”) as described below. On December 9, 2014, December 31, 2014, and February 2, 2015, the Company sold an additional $46,000, $85,000 and $210,000, respectively, of principal amount of the Notes and Warrants to various accredited investors. This private placement, which generated aggregate gross proceeds of $579,500, was terminated effective February 18, 2015. When initially issued, the outstanding principal balance of each Note and all accrued and unpaid interest, compounded annually at 10%, was due and payable in full on September 15, 2015. As discussed below, the maturity date of the Notes was subsequently extended to September 15, 2016, in accordance with the terms of the Notes. Each Purchaser could elect, at any time, at its option and in its sole discretion, to convert the outstanding principal amount into a fixed number of shares of the Company’s common stock equal to the quotient obtained by dividing the outstanding principal amount, plus any accrued and unpaid interest, by $11.3750. In the case of a Qualified Financing (as defined in the Purchase Agreement), the outstanding principal amount and accrued and unpaid interest under the Notes would automatically convert into common stock at a common stock equivalent price of $11.3750. In the case of an Acquisition (as defined in the Purchase Agreement), the Company could elect to either: (i) convert the outstanding principal amount and all accrued and unpaid interest under the Notes into shares of common stock or (ii) accelerate the maturity date of the Notes to the date of closing of the Acquisition. Each Warrant to purchase shares of common stock was exercisable into a fixed number of shares of common stock of the Company calculated as each Purchaser’s investment amount divided by $11.3750. The Warrants were originally exercisable through September 15, 2015 at a fixed price of $11.3750 per share and did not have any cashless exercise provisions. The shares of common stock issuable upon conversion of the Notes and exercise of the Warrants were not subject to any registration rights. On August 13, 2015, the Company, pursuant to the terms of the Notes, gave the Note holders written notice, thirty days in advance of the September 15, 2015 maturity date of the Notes, of the Company’s election to extend the maturity date of the Notes to September 15, 2016. As a consequence of this election, under the terms of the Notes, the Company issued to Note holders 27,396 additional warrants (the “New Warrants”) that were exercisable through September 15, 2016. As set forth in the Notes, the New Warrants were exercisable for that number of shares of common stock of the Company calculated as the principal amount of the Notes (an aggregate amount of $579,500), plus any accrued and unpaid interest (an aggregate amount of $43,758), multiplied by 50%, and then divided by $11.3750. The New Warrants otherwise had terms substantially similar to the 50,945 Warrants originally sold to investors. In connection with the extension of the maturity date of the Notes, the Board of Directors of the Company also determined to extend the termination date of the 50,945 original Warrants to September 15, 2016, so that they were coterminous with the new maturity date of the Notes. The Company used the Black-Scholes option-pricing model to estimate the fair value of the New Warrants to purchase 27,396 shares of the Company’s common stock and the fair value of extending the termination date of the 50,945 original Warrants sold to investors. The Company considered the face value of the Notes, plus the accrued interest thereon, to be representative of their fair value. The relative fair value method generated respective fair values for each of the Notes, including accrued interest, and the New Warrants and extension of the original Warrants, of approximately 55% for the Notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original Warrants. The 45% value attributed to the New Warrants and extension of the original Warrants of $277,918 was amortized as additional interest expense over the extended term of the Notes. During April and May 2016, the Company entered into Note Exchange Agreements with certain note holders representing an aggregate of $303,500 of principal amount of the Notes (out of a total of $579,500 of original principal amount of the Notes). Pursuant to the Note Exchange Agreements, an aggregate of $344,483, which included accrued interest of $40,983, of the Notes were exchanged (together with original warrants to purchase 26,681 shares of the Company’s common stock, New Warrants to purchase 14,259 shares of the Company’s common stock, and the payment of an aggregate of $232,846 in cash) into a total of 101,508 shares of the Company’s common stock. None of the Notes had previously been converted into shares of the Company’s common stock. For accounting purposes, for those convertible note holders accepting the Company’s exchange offer, the Company evaluated the fair value of the incremental consideration paid to induce the convertible note holders to exchange their convertible notes for equity (i.e., 30,284 shares of common stock), based on the closing market price of the Company’s common stock on the date of each transaction, and recorded a charge to operations of $188,274. During year ended December 31, 2016, in connection with the Note Exchange Agreements, the Company wrote off and charged to interest expense the unamortized discount related to the value attributed to the New Warrants and the extension of the original Warrants of $66,811, and the unamortized discount related to the value attributed to the related beneficial conversion feature of $49,688. On September 15, 2016, the remaining outstanding Notes previously issued by the Company on November 5, 2014, December 9, 2014, December 31, 2014, and February 2, 2015, matured and the principal and accrued interest under those remaining Notes became due and payable upon demand. At the September 15, 2016 maturity date, Notes totaling $329,261, which included accrued interest of $53,261, became due and payable upon demand. During October 2016, holders of four Notes issued formal notices of default, and as a result, those four Notes were deemed to be in default under the terms of the Notes and began to accrue interest at the default rate of 12% per annum from the default date in accordance with the terms of the Notes. As of September 30, 2017 such notes remained in default and totaled $82,305, including accrued interest of $21,305. Additionally, on September 15, 2016, the remaining outstanding 13,137 New Warrants and 24,264 original Warrants (which had been previously extended) expired. The Notes (including those placed in default as described above) consist of the following at September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Principal amount of notes payable $ 276,000 $ 276,000 Add accrued interest payable 90,667 62,616 $ 366,667 $ 338,616 As of September 30, 2017, the remaining outstanding Notes were convertible into 32,239 shares of the Company’s common stock, including 7,971 shares attributable to accrued interest of $90,668 payable as of such date. As of December 31, 2016, the Notes were convertible into 29,768 shares of the Company’s common stock, including 5,505 shares attributable to accrued interest of $62,616 payable as of such date. Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 United States Dollars) from and executed a secured note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”), an approximately 20% common stockholder of the Company at that time. SY Corporation was a significant stockholder and a related party at the time of the transaction, but has not been a significant stockholder or related party of the Company subsequent to December 31, 2014. The note accrues simple interest at the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory note. At June 30, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not issued a notice of default or a demand for repayment. The Company believes that SY Corporation is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company is continuing efforts towards a comprehensive resolution of the aforementioned matters involving SY Corporation. The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression. Note payable to SY Corporation consists of the following at September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 255,243 219,362 Foreign currency translation adjustment 5,599 (25,129 ) $ 660,616 $ 594,007 Interest expense with respect to this promissory note was $12,092 and $12,092 for each of the three months ended September 30, 2017 and 2016, respectively. Interest expense with respect to this promissory note was $35,881 and $36,013 for nine months ended September 30, 2017 and 2016, respectively. Advances and Notes Payable to Officers On January 29, 2016, Dr. Arnold S. Lippa, the Company’s Chief Scientific Officer and Chairman of the Board of Directors, advanced $52,600 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. The note was secured by the assets of the Company. In connection with the loan, Dr. Lippa was issued a fully vested warrant to purchase 10,309 shares of the Company’s common stock at an exercise price of $5.1025 per share, which was the closing market price of the Company’s common stock on the date of grant. The warrant expires on January 29, 2019 and may be exercised on a cashless basis. The aggregate fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $48,245, and was charged to interest expense as additional consideration for the loan during the nine months ended September 30, 2016. On February 2, 2016, Dr. James S. Manuso, the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, advanced $52,600 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. The note was secured by the assets of the Company. In connection with the loan, Dr. Manuso was issued a fully vested warrant to purchase 8,092 shares of the Company’s common stock at an exercise price of $6.5000 per share, which was the closing market price of the Company’s common stock on the date of grant. The warrant expires on February 2, 2019 and may be exercised on a cashless basis. The aggregate fair value of the warrant, as calculated pursuant to the Black-Scholes option pricing model, was determined to be $48,392, and was charged to interest expense as additional consideration for the loan during the nine months ended September 30, 2016. On September 22, 2016, Dr. James S. Manuso, the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, advanced $25,000 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. The note was secured by the assets of the Company. In connection with the loan, Dr. Manuso was issued a fully vested warrant to purchase 5,000 shares of the Company’s common stock at an exercise price of $5.0000 per share, which was the closing market price of the Company’s common stock on the date of grant. The warrant expires on September 22, 2019 and may be exercised on a cashless basis. The aggregate fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $22,151, and was charged to interest expense as additional consideration for the loan during the nine months ended September 30, 2016. On September 23, 2016, Dr. Arnold S. Lippa, the Company’s Chief Scientific Officer and Chairman of the Board of Directors, advanced $25,000 to the Company for working capital purposes under a demand promissory note with interest at 10% per annum. The note was secured by the assets of the Company. In connection with the loan, Dr. Lippa was issued a fully vested warrant to purchase 5,155 shares of the Company’s common stock at an exercise price of $4.8500 per share, which was the closing market price of the Company’s common stock on the date of grant. The warrant expires on September 23, 2019 and may be exercised on a cashless basis. The aggregate fair value of the warrant, as calculated pursuant to the Black-Scholes option pricing model, was determined to be $22,152, and was charged to interest expense as additional consideration for the loan during the nine months ended September 30, 2016. During the three months and nine months ended September 30, 2017, $3,912 and $11,608 was charged to interest expense in respect to the four officer notes described above, respectively. During the three months and nine months ended September 30, 2016, $2,754 and $7,106 was charged to interest expense in respect to the four officer notes described above, respectively.

Settlements

Settlements	9 Months Ended
	Sep. 30, 2017
Settlements
Settlements	5. Settlements On June 27, 2016, the Company issued 16,453 of its common stock valued at $96,250 ($5.85 per share), which was the then closing market price of the Company’s common stock, in payment of legal fees to one of its patent law firms. The Company continues to explore ways to reduce its indebtedness, and might in the future enter additional settlements of potential claims, including, without limitation, those by other former executives or third party creditors.

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Deficiency	6. Stockholders’ Deficiency Preferred Stock The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of September 30, 2017 and December 31, 2016, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”); 37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”); 205,000 shares were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating Preferred Stock”); and 1,700 shares were designated as Series G 1.5% Convertible Preferred Stock. Accordingly, as of September 30, 2017 and December 31, 2016, 3,505,800 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. There were no shares of 9% Preferred Stock, Series A Junior Participating Preferred Stock, or Series G 1.5% Convertible Preferred Stock outstanding as of September 30, 2017 and December 31, 2016. Series B Preferred Stock outstanding as of September 30, 2017 and December 31, 2016 consisted of 37,500 shares issued in a May 1991 private placement. Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208,375 per share of common stock, which is subject to adjustment under certain circumstances. As of September 30, 2017 and December 31, 2016, the shares of Series B Preferred Stock outstanding are convertible into 11 shares of common stock. The Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share of Series B Preferred Stock, an amount equal to its liquidation preference, at any time upon 30 days prior notice. Series G 1.5% Convertible Preferred Stock On March 18, 2014 and April 17, 2014, the Company entered into Securities Purchase Agreements with various accredited investors (the “Initial Purchasers”), pursuant to which the Company sold an aggregate of 928.50 shares of its Series G 1.5% Convertible Preferred Stock for a purchase price of $1,000 per share, or an aggregate purchase price of $928,500. On April 17, 2016, the remaining unconverted 259.7 shares of Series G 1.5% Convertible Preferred Stock outstanding (including accrued but unpaid dividends) were automatically and mandatorily redeemed by conversion into 242,173 newly issued shares of common stock at a conversion price of $1.0725 per share. Common Stock On August 16, 2016, at a special meeting of the stockholders of the Company, the stockholders approved an amendment to the Company’s Second Restated Certificate of Incorporation (i) to effect, at the discretion of the Company’s Board of Directors, a three hundred twenty five-to-one (325-to-1) reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.001 per share, and (ii) to set the number of the Company’s authorized shares of stock at 70,000,000 shares, consisting of 65,000,000 shares designated as common stock, par value $0.001 per share, and 5,000,000 shares designated as preferred stock, par value $0.001 per share. On September 1, 2016, the Company filed a Certificate of Amendment to the Company’s Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the approved amendment. Pursuant to the amendment, an aggregate of 191.068 fractional shares resulting from the reverse stock split were not issued, but were to be paid out in cash (without interest or deduction) in an amount equal to the number of shares exchanged into such fractional share multiplied by the average closing trading price of the Company’s common stock on the OTCQB for the five trading days immediately before the Certificate of Amendment effecting the reverse stock split was filed with the Delaware Secretary of State ($6.7899 per share, on a post reverse stock split basis) for an aggregate of $1,298. Unit Exchange Agreements During April and May 2016, the Company entered into Unit Exchange Agreements with certain warrant holders who had acquired units in connection with the Second Amended and Restated Common Stock and Warrant Purchase Agreement on August 28, 2015, September 28, 2015 or November 2, 2015. The Unit Exchange Agreements provided for the warrant holders to exchange (i) existing warrants to purchase an aggregate of 217,187 shares of the Company’s common stock, plus (ii) an aggregate of $529,394 in cash, in return for (i) an aggregate of 108,594 shares of the Company’s common stock with a total market price of $728,859 (average $6.7275 per share), and (ii) new warrants to purchase an aggregate of 108,594 shares of the Company’s common stock with an exercise price of $4.8750 per share, exercisable for cash or on a cashless basis through the original expiration date of September 30, 2020. For accounting purposes, for those unit warrant holders accepting the Company’s exchange offer, the Company evaluated the fair value of the incremental consideration paid to induce the unit warrant holders to exchange their original warrants for exchanged warrants and determined that the Company did not incur any cost with respect to the exchange transactions. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of the exchange consideration is provided at Note 3. 1st 2016 Unit Offering On January 8, 2016, the Company initiated the 1 st Included in the gross proceeds of $309,985 received was $25,350 received on June 30, 2016 from the sale of 3,517 shares of common stock and an aggregate of 7,034 warrants to an unrelated entity with which the Company simultaneously entered into a one-year agreement for investor relations services. The unit price in the 1 st In the case of an acquisition in which the Company is not the surviving entity, the holder of the warrant would receive from any surviving entity or successor to the Company, in exchange for the warrant, a new warrant from the surviving entity or successor to the Company, substantially in the form of the existing warrant and with an exercise price adjusted to reflect the nearest equivalent exercise price of common stock (or other applicable equity interest) of the surviving entity that would reflect the economic value of the warrant, but in the surviving entity. No registration rights were granted to the purchasers in the private placement with respect to (i) the shares of common stock issued as part of the units, (ii) the warrants, or (iii) the shares of common stock issuable upon exercise of the warrants. No placement agent fees, brokerage commissions, finder’s fees or similar payments were made in the form of cash or warrants to qualified referral sources in connection with the sale of the shares of common stock and warrants. The Company paid $3,429 in cash to other professionals for services related to the seven closings. 2nd 2016 Unit Offering On December 29, 2016, the Company entered into purchase agreements with certain accredited investors, pursuant to which, the Company sold units in a private placement for aggregate cash consideration of $125,000, with each unit consisting of (i) one share of common stock, and (ii) one warrant to purchase an additional share of common stock. On December 30, 2016, the Company sold additional units to additional investors for aggregate cash consideration of $60,000 in a second and final closing, bringing the total aggregate consideration paid in the private placement to $185,000 through December 31, 2016. On December 31, 2016, the private placement terminated pursuant to its terms. The price per unit in the initial closing of the 2 nd In addition, as set forth in the agreements, each purchaser has the option, but not the obligation, to exchange the entire amount invested in the private placement (but not less than the entire amount), in such purchaser’s sole discretion, into any subsequent offering of the Company until the earlier of (i) the completion of subsequent offerings by the Company aggregating at least $15 million of gross proceeds to the Company, or (ii) December 31, 2017. If exchanged, the amount to be invested in a subsequent offering will be 1.2 times the amount of the initial investment in the private placement, or 1.4 times the amount of the initial investment if the Company has entered into financing transactions pursuant to Sections 3(a)(9) or 3(a)(10) of the Securities Act of 1933, as amended, or other financing arrangements that have full-ratchet anti-dilution provisions (i) without a floor, or (ii) with an indeterminate and potentially infinite number of shares issuable pursuant to such provisions. If neither termination condition has been reached, and the Company has more than one subsequent offering, the purchaser may elect to exchange into any subsequent offering, regardless of whether such purchaser has already exchanged into a subsequent offering; provided, however, that the amount invested in such subsequent offering will only and always be 1.2 (or 1.4, as applicable) times the amount of the initial investment. In the case of an acquisition, as defined in the agreement, a) in which the Company is not the surviving entity, the holder of each warrant would receive from any surviving entity or successor to the Company, in exchange for such warrant, a new warrant from the surviving entity or successor to the Company, substantially in the form of the existing warrant and with an exercise price adjusted to reflect the nearest equivalent exercise price of common stock (or other applicable equity interest) of the surviving entity that would reflect the economic value of the warrant, but in the surviving entity. Unlimited piggy-back registration rights have been granted with respect to the common stock, and the common stock underlying the warrants, unless such common stock is eligible to be sold without volume limits under an exemption from registration under any rule or regulation of the SEC that permits the holder to sell securities of the Company to the public without registration. The Company is obligated to pay placement agent fees, brokerage commissions, finder’s fees or similar payments totaling up to $13,875 to an unaffiliated qualified referral source as well as warrants up to 7.5% of number of units sold in the private placement. The Company paid $4,000 in cash to other professionals for services related to the closings. The shares of common stock and warrants were offered and sold without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. None of the shares of common stock issued as part of the units, the warrants, the common stock issuable upon exercise of the warrants or any warrants issued to a qualified referral source have been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company evaluated whether the warrants or the exchange rights met criteria to be accounted for as a derivative in accordance with Accounting Standard Codification (ASC) 815, and determined that the derivative criteria were not met. Therefore, the Company determined no bifurcation and separate valuation was necessary and the warrants and exchange right should be accounted for with the host instrument. At each reporting period, the Company analyzed how the host instrument should be classified and determined, at December 31, 2016 and March 31, 2017, that it could not be classified as permanent equity due to the possibility that the Unit investment amount could be exchanged for debt (convertible or otherwise) or for redeemable preferred stock. Because the exchange right expires within one year, the Company concluded that the Unit investment, at that time, would be appropriately classified as a current liability. On July 26, 2017, the Company’s Board approved an offering of securities conducted via private placement that, because of the terms of the new offering as compared to the terms of the 2 nd nd The closing market prices of the Company’s common stock on December 29, 2016 and December 30, 2016 were $2.85 and $2.80 respectively. 1 st On March 10, 2017 and March 28, 2017, the Company sold units to investors in the 1 st st nd On July 26, 2017, the Company’s Board approved an offering of securities conducted via private placement (“2 nd nd st st nd The closing market prices of the Company’s common stock on March 10, 2017 and March 28, 2017 were $4.05 and $3.80 respectively. 2 nd On August 29, 2017, September 27, 2017 and September 28, 2017, the Company sold units to investors for aggregate gross proceeds of $126,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (2 nd nd nd nd The terms of the 2 nd st st nd nd st nd nd Information with respect to the issuance of common stock in connection with the settlement of debt obligations is provided at Note 5. Common Stock Warrants Information with respect to the issuance and exercise of common stock purchase warrants in connection with the 10% Convertible Note Payable and Warrant Purchase Agreement is provided at Note 4. A summary of warrant activity for the nine months ended September 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2016 540,198 $ 4.84842 Issued 445,717 1.36478 Warrants outstanding at September 30, 2017 985,915 $ 3.27352 4.7567 Warrants exercisable at December 31, 2016 540,198 $ 4.84842 Warrants exercisable at September 30, 2017 985,915 $ 3.27352 4.7567 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2017: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 0 0 December 31, 2021 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,005 86,005 February 28, 2021 $ 2.7500 108,000 108,000 December 31, 2021 $ 1.1000 468,000 468,000 September 29, 2022 985,915 985,915 Based on a fair market value of $1.40 per share on September 30, 2017, the intrinsic value of exercisable in-the-money common stock warrants was $144,633 as of September 30, 2017. A summary of warrant activity for the nine months ended September 30, 2016 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2015 482,288 $ 7.10125 Issued, net of exercises and expirations (72,374 ) $ (1.03629 ) Warrants outstanding at September 30, 2016 409,914 $ 5.89296 3.84 Warrants exercisable at December 31, 2015 482,288 $ 7.10125 Warrants exercisable at September 30, 2016 409,914 $ 5.89296 3.84 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2016: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1,2870 41,002 41,002 April 17, 2019 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 409,914 409,914 Based on a fair market value of $4.4900 per share on September 30, 2016, the intrinsic value of exercisable in-the-money common stock warrants was $131,329 as of September 30, 2016. Stock Options In connection with the initial closing of the Series G Private Placement completed on March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 325,025 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (the “2015 Plan”). The 2015 Plan initially provided for, among other things, the issuance of either or any combination of restricted shares of common stock and non-qualified stock options to purchase up to 461,538 shares of the Company’s common stock for periods up to ten years to management, members of the Board of Directors, consultants and advisors. The Company has not and does not intend to present the 2015 Plan to stockholders for approval. On August 18, 2015, the Board of Directors increased the number of shares that may be issued under the 2015 Plan to 769,231 shares of the Company’s common stock. On March 31, 2016, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 1,538,461 shares of the Company’s common stock. On January 17, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 3,038,461 shares of the Company’s common stock. On March 31, 2016, the Board of Directors of the Company awarded stock options for a total of 523,075 shares of common stock in various quantities to twelve individuals who are members of management, the Company’s Scientific Advisory Board, independent members of the Board of Directors, or outside service providers pursuant to the Company’s 2015 Plan. The stock options vested 25% on each of March 31, 2016, June 30, 2016, September 30, 2016 and 25% on December 31, 2016, and will expire on March 31, 2021. The exercise price of the stock options was established on the grant date at $7.3775 per share, which was the closing market price of the Company’s common stock on such date. The aggregate fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was $3,774,000. During the three months ended March 31, 2016 and nine months ended September 30, 2016, the Company recorded charges to operations of $844,650 and $2,686,800, respectively, with respect to these stock options. On September 12, 2016, the Company entered into an agreement for consulting services, which provided for the payment of a fee through the granting of a non-qualified stock option to purchase a total of 2,608 shares of common stock pursuant to the Company’s 2015 Plan. The stock option was fully vested on the date of grant and will expire on September 12, 2021. The exercise price of the stock option was established on the grant date at $5.7500 per share, which was the closing market price of the Company’s common stock on the date of grant. The aggregate fair value of the stock option, calculated pursuant to the Black-Scholes option-pricing model, was $14,384, which was charged to operations on the date of grant. On January 17, 2017, the Board of Directors of the Company awarded stock options for a total of 395,000 shares of common stock in various quantities to seventeen individuals and entities who are members of management, the Company’s Scientific Advisory Board, independent members of the Board of Directors, or outside service providers pursuant to the Company’s 2015 Plan. The stock options vested 25% upon grant, 25% on March 31, 2017, and an additional 50% on June 30, 2017, and will expire on January 17, 2022. The exercise price of the stock options was established on the grant date at $3.90 per share, which was the closing market price of the Company’s common stock on such date. The aggregate fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was $1,464,305. During the nine months ended September 30, 2017, the Company recorded a charge to operations of $1,216,378 with respect to these stock options. On June 30, 2017, the Board of Directors of the Company awarded stock options for a total of 285,000 shares of common stock in various quantities to nine individuals who are members of management, independent members of the Board of Directors, or outside service providers pursuant to the Company’s 2015 Plan. The stock options vested immediately upon grant. The exercise price of the stock options was established on the grant date at $2.00 per share, which was the closing market price of the Company’s common stock on the date of the grant. The aggregate fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was $505,875. During the nine months ended September 30, 2017, the Company recorded a charge to operations of $505,875 with respect to these stock options. On July 26, 2017, the Board of Directors of the Company awarded stock options for a total of 25,000 shares of common stock to one individual who is a member of management pursuant to the Company’s 2015 Plan. The stock options vested 25% upon grant, 25% on September 30, 2017 and will vest 50% on December 31, 2017. The exercise price of the options was established on the grant date at $2.00, which was above the closing market price of the Company’s common stock on that date which was $1.30. The aggregate fair value of these stock options, as calculated pursuant to the Black Scholes option pricing model, was $27,225. During the three months and nine months ended September 30, 2017, the Company recorded a charge to operations of $13,613 with respect to these options. On July 28, 2017, the Board of Directors of the Company awarded stock options for a total of 34,000 shares of common stock to two individuals who are consultants pursuant to the Company’s 2015 Plan. With respect to one individual, the 9,000 options vested 33 1/3% upon grant, 33 1/3 % on August 31, 2017 and 33 1/3% on September 30, 2017 such that all options vested by September 30, 2017. With respect to the other individual, the 25,000 options vest 20% on each of August 31, 2017, September 30, 2017, October 31, 2017, November 30, 2017 and December 31, 2017. The exercise price of the options was established on the grant date at $1.35, which was the closing market price of the Company’s common stock on the date of the grant. The aggregate fair value of these stock options, as calculated pursuant to the Black Scholes option pricing model, was $39,807. During the three months and nine months ended September 30, 2017, the Company recorded a charge to operations of $22,257 with respect to these stock options. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock-based compensation is provided at Note 3. A summary of stock option activity for the nine months ended September 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2016 1,307,749 $ 7.6515 Granted 739,000 Options outstanding at September 30, 2017 2,046,749 $ 6.0125 4.54 Options exercisable at December 31, 2016 1,307,749 $ 7.6515 Options exercisable at September 30, 2017 2,019,249 $ 6.0125 4.54 Deferred compensation expense for outstanding and unvested stock options at September 30, 2017 was $27,500 and was $0 at December 31, 2016. The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2017: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 1.3500 34,000 19,000 July 28, 2022 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 12,500 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 2,046,749 2,019,249 Based on a fair market value of $1.40 per share on September 30, 2017, exercisable in-the-money common stock options had an intrinsic value of $950.00. A summary of stock option activity for the nine months ended September 30, 2016 is presented below. Number of Shares Weighted Average Exercise Price Weighted Remaining Contractual Life (in Years) Options outstanding at December 31, 2015 774,842 $ 7.8325 Granted 532,907 7.3305 Options outstanding at September 30, 2016 1,307,749 $ 7.6241 5.56 Options exercisable at December 31, 2015 519,662 $ 8.5150 Options exercisable at September 30, 2016 1,177,364 $ 7.6515 5.68 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2016: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 4.500 7,222 7,222 September 2, 2021 $ 5.7500 2,608 2,608 September 12, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 392,692 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.2500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.500 6,410 6,410 August 10, 2022 1,307,749 1,177,364 Based on a fair market value of $4.49 per share on September 30, 2016, the intrinsic value of exercisable in-the-money common stock options was $0 as of September 30, 2016. For the three months ended September 30, 2017 and 2016, stock-based compensation costs included in the condensed consolidated statements of operations consisted of general and administrative expenses of $23,873 and $837,630, respectively, and research and development expenses of $11,700 and $328,462, respectively. For the nine months ended September 30, 2017 and 2016, stock-based compensation costs included in the condensed consolidated statements of operations consisted of general and administrative expenses of $1,150,925 and $2,821,748, respectively, and research and development expenses of $606,901 and $1,129,526, respectively. Pier Contingent Stock Consideration In connection with the merger transaction with Pier effective August 10, 2012, RespireRx issued 179,747 newly issued shares of its common stock with an aggregate fair value of $3,271,402 ($18.2000 per share), based upon the closing price of RespireRx’s common stock on August 10, 2012. The shares of common stock were distributed to stockholders, convertible note holders, warrant holders, option holders, and certain employees and vendors of Pier in satisfaction of their interests and claims. The common stock issued by RespireRx represented approximately 41% of the 443,205 common shares outstanding immediately following the closing of the transaction. Pursuant to the terms of the transaction, RespireRx agreed to issue additional contingent consideration, consisting of up to 56,351 shares of common stock, to Pier’s former security holders and certain other creditors and service providers (the “Pier Stock Recipients”) that received RespireRx’s common stock as part of the Pier transaction if certain of RespireRx’s stock options and warrants outstanding immediately prior to the closing of the merger were subsequently exercised. In the event that such contingent shares were issued, the ownership percentage of the Pier Stock Recipients, following their receipt of such additional shares, could not exceed their ownership percentage as of the initial transaction date. The stock options and warrants outstanding at June 30, 2012 were all out-of-the-money on August 10, 2012. During late July and early August 2012, shortly before completion of the merger, the Company issued options to officers and directors at that time to purchase a total of 22,651 shares of common stock exercisable for ten years at $19.5000 per share. By October 1, 2012, these options, as well as the options and warrants outstanding at June 30, 2012, were also out-of-the-money and continued to be out-of-the-money through June 30, 2017. There were no stock options or warrants exercised subsequent to August 10, 2012 that triggered additional contingent consideration, and the only remaining stock options outstanding that could still trigger the additional contingent consideration remained out-of-the-money through September 30, 2017. As of September 30, 2017, due to the expirations and forfeitures of RespireRx stock options and warrants occurring since August 10, 2012, 6,497 contingent shares of common stock remained issuable under the Pier merger agreement. The Company concluded that the issuance of any of the contingent shares to the Pier Stock Recipients was remote, as a result of the large spread between the exercise prices of these stock options and warrants as compared to the common stock trading range, the subsequent expiration or forfeiture of most of the options and warrants, the Company’s distressed financial condition and capital requirements, and that these stock options and warrants have remained significantly out-of-the-money through September 30, 2017. Accordingly, the Company considered the fair value of the contingent consideration to be immaterial and therefore did not ascribe any value to such contingent consideration. If any such shares are ultimately issued to the former Pier stockholders, the Company will recognize the fair value of such shares as a charge to operations at that time. Reserved and Unreserved Shares of Common Stock On January 17, 2017, the Board of Directors of the Company approved the adoption of the Amendment of the Amended and Restated RespireRx Pharmaceuticals, Inc. 2015 Stock and Stock Option Plan (the “2015 Plan”). The Amendment increases the shares issuable under the plan by 1,500,000, from 1,538,461 to 3,038,461. Other than the change in the number of shares available under the 2015 Plan, no other changes were made to the 2015 Plan by the Amendment. At September 30, 2017, the Company had 65,000,000 shares of common stock authorized and 2,586,761 shares of common stock issued and outstanding. Furthermore, as of September 30, 2017, the Company had reserved an aggregate of 11 shares for issuance upon conversion of the Series B Preferred Stock; 688,198 shares for issuance upon exercise of warrants; 2,046,749 shares for issuance upon exercise of outstanding stock options; 63,236 shares to cover equity grants available for future issuance pursuant to the 2014 Plan; 1,053,201 shares to cover equity grants available for future issuance pursuant to the 2015 Plan; 32,239 shares for issuance upon conversion of the Convertible Notes; and 6,497 shares issuable as contingent shares pursuant to the Pier merger. Accordingly, as of September 30, 2017, the Company had an aggregate of 3,890,131 shares of common stock reserved for issuance and 58,523,108 shares of common stock unreserved and available for future issuance. The Company expects to satisfy its future common stock commitments through the issuance of authorized but unissued shares of common stock.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests and managing memberships in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora is a boutique investment banking firm specializing in the life sciences sector that is also a full service brokerage firm. On March 31, 2013, the Company accrued $85,000 as reimbursement for legal fees incurred by Aurora in conjunction with the removal of the Company’s prior Board of Directors on March 22, 2013, which amount has been included in accounts payable and accrued expenses at September 30, 2017 and December 31, 2016. On June 30, 2015, the Board of Directors of the Company awarded, but did not pay, cash bonuses totaling $215,000, including an aggregate of $195,000 to certain of the Company’s executive officers and an aggregate of $20,000 to the independent members of the Company’s Board of Directors. The cash bonuses awarded to executive officers were as follows: Dr. Arnold S. Lippa - $75,000; Jeff E. Margolis - $60,000; and Robert N. Weingarten (resigned as an officer and director of the Company in February 2017, but remains a consultant to the Company) - $60,000. The cash bonuses awarded to the two independent members of the Company’s Board of Directors were as follows: James E. Sapirstein - $10,000; and Kathryn MacFarlane - $10,000. The cash bonuses were awarded as partial compensation for services rendered by such persons from January 1, 2015 through June 30, 2015, and are included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheet at September 30, 2017 and December 31, 2016. On June 30, 2015, the Board of Directors also established cash compensation arrangements for certain of the Company’s executive officers at the following monthly rates: Dr. Arnold S. Lippa - $12,500; Jeff E. Margolis - $10,000; and Robert N. Weingarten (resigned as an officer and director of the Company in February 2017, but remains a consultant to the Company) - $10,000. In addition, the Company established quarterly cash board fees for the two independent members of the Company’s Board of Directors as follows: James E. Sapirstein - $5,000; and Kathryn MacFarlane - $5,000. This compensation was payable in arrears and commenced on July 1, 2015. These compensation arrangements had been extended through December 31, 2017. On August 18, 2015, the cash compensation arrangements for these executive officers were further revised as described below. Both the cash bonuses and the cash monthly compensation have been accrued and will not be paid until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. The amendment to the Jeff E. Margolis employment agreement effective July 1, 2017, called for payment in three installments in cash of the $60,000 bonus granted on June 30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 shall be payable in cash upon the next closing (after July 1, 2017) of any financing in excess of $100,000 (b) $15,000 by the end of the following month assuming cumulative closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 shall be payable in cash upon the next closing of any financing in excess of an additional $250,000 . On March 28, 2017, Aurora earned $20,000 of cash fees and 8,000 placement agent common stock warrants associated with the closing of 1 st A description of advances and notes payable to officers is provided at Note 4.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Pending or Threatened Legal Actions and Claims By letter dated November 11, 2014, a former director of the Company, who joined the Company’s Board of Directors on August 10, 2012 in conjunction with the Pier transaction and who resigned from the Company’s Board of Directors on September 28, 2012, asserted a claim for unpaid consulting compensation of $24,000. The Company has not received any further communications from the former director with respect to this matter. By letter dated February 5, 2016, the Company received a demand from a law firm representing a professional services vendor of the Company alleging an amount due and owing for unpaid services rendered. On January 18, 2017, following an arbitration proceeding, an arbitrator awarded the vendor the full amount sought in arbitration of $146,082. Additionally, the arbitrator granted the vendor attorneys’ fees and costs of $47,930. All such amounts have been accrued at September 30, 2017 and December 31, 2016. By e-mail dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and owing for unpaid investment banking services rendered. The Company has been in discussions with this firm regarding this matter. The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements at September 30, 2017 and December 31, 2016 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself in the event that any of the matters described above results in the filing of a lawsuit or formal claim. Significant Agreements and Contracts Consulting Agreement Richard Purcell was appointed as the Company’s Senior Vice President of Research and Development effective October 15, 2014. Mr. Purcell provides his services to the Company on a month-to-month basis through his consulting firm, DNA Healthlink, Inc., through which the Company has contracted for his services, for a monthly cash fee of $12,500. Cash compensation expense pursuant to this agreement totaled $37,500 for the three months ended September 30, 2017 and 2016, and totaled $112,500 for the nine months ended September 30, 2017 and 2016, which amounts are included in research and development expenses in the Company’s condensed consolidated statements of operations for such periods. Employment Agreements On August 18, 2015, the Company entered into an employment agreement with Dr. James S. Manuso, Ph.D., to be its new President and Chief Executive Officer. Pursuant to the agreement, which is for an initial term through September 30, 2018 (and which will be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Manuso received an annual base salary of $375,000. Dr. Manuso is also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Dr. Manuso was granted stock options to acquire 261,789 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans in the discretion of the Board of Directors. Dr. Manuso is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as additional compensation for a term life insurance policy and disability insurance policy. Dr. Manuso is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Dr. Manuso is provided at Note 7. Cash compensation accrued pursuant to this agreement totaled $103,650 and $310,950 for the three months and nine months ended September 30, 2017, respectively, and $103,650 and $317,700 for the three months and nine months ended September 30, 2016, respectively. Such amounts are included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheets at September, 2017 and 2016, respectively, and in general and administrative expenses in the Company’s condensed consolidated statements of operations for the three months and nine months ended September 30, 2017 and 2016. Dr. Manuso was also appointed to the Company’s Board of Directors and elected as Vice Chairman of the Board of Directors. Dr. Manuso will not receive any additional compensation for serving as Vice Chairman and on the Board of Director. Such amounts have not been paid to Dr. Manuso. On August 18, 2015, concurrently with the hiring of Dr. James S. Manuso as the Company’s new President and Chief Executive Officer, Dr. Arnold S. Lippa resigned as the Company’s President and Chief Executive Officer. Dr. Lippa continues to serve as the Company’s Executive Chairman and as a member of the Board of Directors. Also on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the Company, and the Company entered into an employment agreement with Dr. Lippa in that capacity. Pursuant to the agreement, which is for an initial term through September 30, 2018 (and which will be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Lippa received an annual base salary of $300,000. Dr. Lippa is also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Dr. Lippa was granted stock options to acquire 30,769 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Dr. Lippa is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Dr. Lippa is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Dr. Lippa is provided at Note 7. Cash compensation accrued pursuant to this agreement totaled $84,900 and $254,700 for the three months and nine months ended September 30, 2017, respectively, and $93,900 and $254,700 for the three months and nine months ended September 30, 2016, respectively, which is included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheets at September 30, 2017 and 2016, and in research and development expenses in the Company’s condensed consolidated statements of operations. Cash compensation accrued to Dr. Lippa for bonuses and under a prior superseded arrangement, while still serving as the Company’s President and Chief Executive Officer, totaled $94,758 and is included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheets at September 30, 2017 and 2016, and in general and administrative expenses in the Company’s condensed consolidated statements of operations. Such amounts have not been paid to Dr. Lippa. Dr. Lippa does not receive any additional compensation for serving as Executive Chairman and on the Board of Directors. On August 18, 2015, the Company also entered into employment agreements with Jeff E. Margolis, in his continuing role as Vice President, Secretary and Treasurer, and Robert N. Weingarten, in his continuing role as Vice President and Chief Financial Officer, the position from which he resigned in February 2017. Mr. Weingarten remains a consultant to the Company. Pursuant to the agreements, which are for initial terms through September 30, 2016 (and which, for Mr. Margolis, will be deemed to be automatically extended upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Mr. Margolis and Mr. Weingarten, until his resignation, each received an annual base salary of $195,000, and since Mr. Weingarten’s resignation, only Mr. Margolis is eligible to receive performance-based annual bonus awards ranging from $65,000 to $125,000, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Mr. Margolis and Mr. Weingarten were each granted stock options to acquire 30,769 shares of common stock of the Company and both are eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Mr. Weingarten remains eligible for additional awards as he remains a consultant to the Company. Mr. Margolis and Mr. Weingarten (until his resignation), are/were also each entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Both Mr. Margolis and Mr. Weingarten are also each entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Mr. Margolis and Mr. Weingarten is provided at Note 7. Cash compensation accrued pursuant to these agreements were $80,400 and $188,700 for Mr. Margolis for the three months and nine months ended September, 2017 and were $54,150 and $162,450 for the three and nine months ended September 30, 2016, respectively, and were $0 and $28,524 for Mr. Weingarten for the three months and nine months ended September 30, 2017, respectively, and $54,150 and $162,450 for the three months and nine months ended September 30, 2016, respectively, which is included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheets at September 30, 2017 and 2016, and in general and administrative expenses in the Company’s condensed consolidated statements of operations. Cash compensation accrued to Mr. Margolis and Mr. Weingarten for bonuses and under prior superseded arrangements totaled $151,612 ($75,806 each) and is also included in accrued compensation and related expenses in the Company’s condensed consolidated balance sheets at September 30, 2017 and 2016, and in general and administrative expenses in the Company’s condensed consolidated statements of operations. Such amounts have not been paid to Mr. Margolis or Mr. Weingarten. Mr. Margolis also continues to serve as a Director of the Company, but does not receive any additional compensation for serving on the Board of Directors. Mr. Margolis’ employment agreement was amended effective July 1, 2017. By Unanimous Written Consent on June 30, 2017, the Board of Directors of the Company resolved to amend the Employment Agreement with Jeff Margolis effective July 1, 2017. The amendment provides that Jeff Margolis will have the additional title of Chief Financial Officer and be promoted from Vice President to Senior Vice President. The amendment also provides for an increase in the accrual rate of his cash compensation from $195,000 to $300,000 annually. The amendment also schedules a cash payment of a bonus granted on June 30, 2015 as follows: (a) $15,000 payable upon the closing of the next financing in excess of $100,000, (b) $15,000 payable by the end of the following month assuming cumulative closings on financings (commencing with the closing that triggered (a)) of at least $200,000, and (c) $30,000 upon the closing of the next financing in excess of an additional $250,000. Jeff Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. The amendment also provides for an option grant of 25,000 non-qualified stock options to be granted on or about July 1, 2017. By Unanimous Written Consent on July 26, 2017, the Board of Directors resolved to make such grant with 25% of such options vesting immediately, 25% vesting on September 30, 2017 and 50% vesting on December 31, 2017 at an exercise price of the greater of $2.00 or the closing price of the Company’s common stock on the date of the grant (July 26, 2017), which resulted in an exercise price of $2.00. The amendment further provides that Mr. Margolis will participate in future executive bonus, option, equity and equity-linked grants or other fringe benefits (including, for example, auto, life insurance, health insurance, and expense allowance) in accordance with the terms of the employment contract, amended to reflect that such grants shall be at least equal to the lowest grant to any member or the executive management team (meaning any person with a title of Senior Vice President, Chief Financial Officer, or higher) regardless of whether such executive officer is also a member of the Board of Directors. An exception to this clause provided that any signing bonus, equity, option or similar grant necessary to induce the hiring of a Chief Financial Officer, Chief Medical Officer, or other executive officer. The employment agreement was automatically extended to September 30, 2017 after which it would be subject to one year extensions in a manner the same as that prior to the amendment. The employment agreements between the Company and each of Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten, respectively, provided that the payment obligations associated with the first year base salary were to accrue, but no payments were to be made, until at least $2,000,000 of net proceeds from any offering or financing of debt or equity, or a combination thereof, was received by the Company, at which time scheduled payments were to commence. This financing milestone has been achieved, however, Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten (who are, or in Mr. Weingarten’s case was, each also directors of the Company) have each agreed, effective as of August 11, 2016, to continue to defer the payment of such amounts indefinitely, until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. University of California, Irvine License Agreements The Company entered into a series of license agreements in 1993 and 1998 with the University of California, Irvine (“UCI”) that granted the Company proprietary rights to certain chemical compounds that acted as ampakines and to their therapeutic uses. These agreements granted the Company, among other provisions, exclusive rights: (i) to practice certain patents and patent applications, as defined in the license agreement, that were then held by UCI; (ii) to identify, develop, make, have made, import, export, lease, sell, have sold or offer for sale any related licensed products; and (iii) to grant sub-licenses of the rights granted in the license agreements, subject to the provisions of the license agreements. The Company was required, among other terms and conditions, to pay UCI a license fee, royalties, patent costs and certain additional payments. Under such license agreements, the Company was required to make minimum annual royalty payments of approximately $70,000. The Company was also required to spend a minimum of $250,000 per year to advance the ampakine compounds until the Company began to market an ampakine compound. The commercialization provisions in the agreements with UCI required the Company to file for regulatory approval of an ampakine compound before October 2012. In March 2011, UCI agreed to extend the required date for filing regulatory approval of an ampakine compound to October 2015. During December 2012, the Company informed UCI that it would be unable to make the annual payment due to a lack of funds. The Company believes that this notice, along with its subsequent failure to make its minimum annual payment obligation, constituted a default and termination of the license agreements. On April 15, 2013, the Company received a letter from UCI indicating that the license agreements between UCI and the Company had been terminated due to the Company’s failure to make certain payments required to maintain the agreements. Since the patents covered in these license agreements had begun to expire and the therapeutic uses described in these patents were no longer germane to the Company’s new focus on respiratory disorders, the loss of these license agreements is not expected to have a material impact on the Company’s current drug development programs. In the opinion of management, the Company has made adequate provision for any liability relating to this matter in its condensed consolidated financial statements at September 30, 2017 and December 31, 2016. University of Alberta License Agreement On May 8, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments. The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling a Phase 2B clinical trial in the near term, no maintenance payments to the University of Alberta are currently due and payable, nor are any maintenance payments expected to be due in the near future in connection with the license agreement. Transactions with Biovail Laboratories International SRL In March 2010, the Company entered into an asset purchase agreement with Biovail Laboratories International SRL (“Biovail”). Pursuant to the asset purchase agreement, Biovail acquired the Company’s interests in CX717, CX1763, CX1942 and the injectable dosage form of CX1739, as well as certain of its other ampakine compounds and related intellectual property for use in the field of respiratory depression or vaso-occlusive crises associated with sickle cell disease. The agreement provided the Company with the right to receive milestone payments in an aggregate amount of up to $15,000,000 plus the reimbursement of certain related expenses, conditioned upon the occurrence of particular events relating to the clinical development of certain assets that Biovail acquired. None of these events occurred. As part of the transaction, Biovail licensed back to the Company certain exclusive and irrevocable rights to some acquired ampakine compounds, other than CX717, an injectable dosage form of CX1739, CX1763 and CX1942, for use outside of the field of respiratory depression or vaso-occlusive crises associated with sickle cell disease. Accordingly, following the transaction with Biovail, the Company retained its rights to develop and commercialize the non-acquired ampakine compounds as a potential treatment for neurological diseases and psychiatric disorders. Additionally, the Company retained its rights to develop and commercialize the ampakine compounds as a potential treatment for sleep apnea disorders, including an oral dosage form of ampakine CX1739. In September 2010, Biovail’s parent corporation, Biovail Corporation, combined with Valeant Pharmaceuticals International in a merger transaction and the combined company was renamed “Valeant Pharmaceuticals International, Inc.” (“Valeant”). Following the merger, Valeant and Biovail conducted a strategic and financial review of their product pipeline and, as a result, in November 2010, Biovail announced its intent to exit from the respiratory depression project acquired from the Company in March 2010. Following that announcement, the Company entered into discussions with Biovail regarding the future of the respiratory depression project. In March 2011, the Company entered into a new agreement with Biovail to reacquire the ampakine compounds, patents and rights that Biovail had acquired from the Company in March 2010. The new agreement provided for potential future payments of up to $15,150,000 by the Company based upon the achievement of certain developments, including new drug application submissions and approval milestones. Biovail is also eligible to receive additional payments of up to $15,000,000 from the Company based upon the Company’s net sales of an intravenous dosage form of the compounds for respiratory depression. At any time following the completion of Phase 1 clinical studies and prior to the end of Phase 2A clinical studies, Biovail retains an option to co-develop and co-market intravenous dosage forms of an ampakine compound as a treatment for respiratory depression and vaso-occlusive crises associated with sickle cell disease. In such an event, the Company would be reimbursed for certain development expenses to date and Biovail would share in all such future development costs with the Company. If Biovail makes the co-marketing election, the Company would owe no further milestone payments to Biovail and the Company would be eligible to receive a royalty on net sales of the compound by Biovail or its affiliates and licensees. University of Illinois 2014 Exclusive License Agreement On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment by the Company of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights the Company held in certain patent applications, all of which conditions were fulfilled. The 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015 and also requires the Company to pay the University of Illinois a license fee, royalties, patent costs and certain milestone payments. The 2014 License Agreement provides for various royalty payments by the Company, including a royalty on net sales of 4%, payment on sub-licensee revenues of 12.5%, and a minimum annual royalty of $100,000 beginning in 2015, which is due and payable on December 31 of each year. The 2015 minimum annual royalty of $100,000 was paid as scheduled in December 2015, and the 2016 minimum annual royalty of $100,000 was paid as scheduled in December 2016. In the year after the first application for market approval is submitted to the FDA and until approval is obtained, the minimum annual royalty will increase to $150,000. In the year after the first market approval is obtained from the FDA and until the first sale of a product, the minimum annual royalty payable by the Company will increase to $200,000. In the year after the first commercial sale of a product, the minimum annual royalty will increase to $250,000. The 2014 License Agreement also provides for certain one-time milestone payments by the Company. A payment of $75,000 is due within five days after any one of the following: (a) dosing of the first patient with a product in a Phase 2 human clinical study anywhere in the world that is not sponsored by the University of Illinois, (b) dosing of the first patient in a Phase 2 human clinical study anywhere in the world with a low dose of dronabinol, or (c) dosing of the first patient in a Phase 1 human clinical study anywhere in the world with a proprietary reformulation of dronabinol. A payment of $350,000 is due within five days after dosing of the first patient with a product in a Phase 3 human clinical trial anywhere in the world. A payment of $500,000 is due within five days after the first new drug application filing with the FDA or a foreign equivalent for a product. A payment of $1,000,000 is due within 12 months after the first commercial sale of a product. During each of the three months ended September 30, 2017 and September 30, 2016, the Company recorded charges to operations of $25,000, and during each of the nine months ended September 30, 2017 and 2016, the Company recorded charges to operations of $75,000 with respect to its 2017 and 2016 minimum annual royalty obligation, which is included in research and development expenses in the Company’s condensed consolidated statements of operations for the three months and nine months ended September 30, 2017 and 2016, as appropriate. Research Contract with the University of Alberta On January 12, 2016, the Company entered into a Research Contract with the University of Alberta in order to test the efficacy of ampakines at a variety of dosage and formulation levels in the potential treatment of Pompe Disease, apnea of prematurity and spinal cord injury, as well as to conduct certain electrophysiological studies to explore the ampakine mechanism of action for central respiratory depression. The Company agreed to pay the University of Alberta total consideration of approximately CAD$146,000 (approximately US$112,000), consisting of approximately CAD$85,000 (approximately US$65,000) of personnel funding in cash in four installments during 2016, to provide approximately CAD$21,000 (approximately US$16,000) in equipment, to pay patent costs of CAD$20,000 (approximately US$15,000), and to underwrite additional budgeted costs of CAD$20,000 (approximately US$15,000). As of September 30, 2017, Company has recorded accounts payable to the University of Alberta of US$16,207. The conversion to US dollars above utilized an exchange rate of US$0.77 for every CAD$1.00 which was the exchange rate at the time. The exchange rate as of September 30, 2017 was US$0.80 for every CAD$1.00. The University of Alberta received matching funds through a grant from the Canadian Institutes of Health Research in support of the research. The Company will retain the rights to research results and any patentable intellectual property generated by the research. Dr. John Greer, Chairman of the Company’s Scientific Advisory Board and faculty member of the Department of Physiology, Perinatal Research Centre and Women & Children’s Health Research Institute, and Alberta Innovates - Health Sciences Senior Scientist with the Neuroscience and Mental Health Institute at the University of Alberta, will collaborate on this research. The studies were completed in 2016. National Institute of Drug Abuse Agreement On January 19, 2016, the Company announced that that it has reached an agreement with the Medications Development Program of the National Institute of Drug Abuse (“NIDA”) to conduct research on the Company’s ampakine compounds CX717 and CX1739. The agreement was entered into as of October 19, 2015, and on January 14, 2016, the Company and NIDA approved the proposed protocols, allowing research activities to commence. NIDA will evaluate the compounds using pharmacologic, pharmacokinetic and toxicologic protocols to determine the potential effectiveness of the ampakines for the treatment of drug abuse and addiction. Initial studies will focus on cocaine and methamphetamine addiction and abuse, and will be contracted to outside testing facilities and/or government laboratories, with all costs to be paid by NIDA. The Company will provide NIDA with supplies of CX717 and CX1739 and will work with the NIDA staff to refine the protocols and dosing parameters. The Company will retain all intellectual property, as well as proprietary and commercialization rights to these compounds. Duke University Clinical Trial Agreement On January 27, 2015, the Company entered into a Clinical Study and Research Agreement (the “Agreement”) with Duke University to develop and conduct a protocol for a program of clinical study and research at a total cost of $50,579, which was completed in March 2015 and charged to research and development expenses during the three months ended March 31, 2015. On October 30, 2015, the Agreement was amended to provide for a Phase 2A clinical trial of CX1739 at a cost of $558,268. During March 2016, a Phase 2A clinical trial at Duke University School of Medicine was initiated, with the dosing portion of the clinical trial completed in June 2016 and the clinical trial formally completed on July 11, 2016. On July 28, 2016, the Agreement was further amended to reflect additional post-clinical trial costs of $120,059, increasing the total amount payable under the Agreement to $678,327. During the three months ended September 30, 2017 and 2016, the Company charged $0 and $193,119, respectively, and during the nine months ended September 30, 2017 and 2016, the Company charged $36,420 and $602,642, respectively, to research and development expenses with respect to work conducted pursuant to the amended Agreement. Sharp Clinical Services, Inc. Agreement The Company has various agreements with Sharp Clinical Services, Inc. to provide packaging, labeling, distribution and analytical services. Covance Laboratories Inc. Agreement On October 26, 2016, the Company entered into a twelve month agreement with Covance Laboratories Inc. to provide compound testing and storage services with respect to CX1739, CX1866 and CX1929 at a total budgeted cost of $35,958. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of September 30, 2017, aggregating $1,518,800. Amounts included in the 2017 column represent amounts contractually due at October 1, 2017 through the remainder of the 2017 fiscal year ending December 31, 2017. Payments Due By Year Total 2017 2018 2019 2020 2021 Research and development contracts $ — $ — $ — $ — $ — $ — Clinical trial agreements — — — — — — License agreements 425,000 25,000 100,000 100,000 100,000 100,000 Employment and consulting agreements (1) 1,093,800 273,450 820,350 — — — Total $ 1,518,800 $ 298,450 $ 920,350 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements”.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing these financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the condensed consolidated financial statements, other than those discussed below. 2 nd On October 5, 2017 and October 25, 2017, there were additional closings with respect to the 2 nd nd Unit Offering Exchange On October 1, 2017, one investor from the offering exchanged into the 2 nd nd

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three months when acquired to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms.
Deferred Financing Costs	Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed debt financings are presented as a direct deduction from the carrying amount of the related debt liability (see “Capitalized Financing Costs” below). Costs related to completed equity financings are charged directly to additional paid-in capital.
Capitalized Financing Costs	Capitalized Financing Costs The Company presents debt issuance costs related to a debt liability in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the presentation for debt discounts. As of September 30, 2017 and December 31, 2016, the Company did not have any such capitalized financing costs on its condensed consolidated balance sheets.
Series G 1.5% Convertible Preferred Stock	Series G 1.5% Convertible Preferred Stock The shares of Series G 1.5% Convertible Preferred Stock (including accrued dividends) issued in 2014 were mandatorily convertible into common stock at a fixed conversion rate on April 17, 2016 (if not converted earlier) and provided no right to receive a cash payment. Additionally, the Series G 1.5% Convertible Preferred Stock included no participatory or reset rights, or other protections (other than normal anti-dilution rights) based on subsequent events, including equity transactions. Accordingly, the Company categorized the Series G 1.5% Convertible Preferred Stock in stockholders’ deficiency, as there were no derivatives embedded in such security that would require identification, bifurcation and valuation. The Company did not issue any warrants to investors in conjunction with the Series G 1.5% Convertible Preferred Stock financing.
Convertible Notes Payable	Convertible Notes Payable Original Issuance of Notes and Warrants The convertible notes sold to investors in 2014 and 2015 had a fixed interest rate of 10% per annum and are convertible into common stock at a fixed price of $11.3750 per share. The convertible notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The warrants issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share, provided no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. On November 5, 2014, the Company sold an aggregate principal amount of $238,500 of its convertible notes payable due September 15, 2015, which were subject to extension to September 15, 2016, at the option of the Company, subject to the issuance of additional warrants, and warrants to purchase shares of common stock exercisable into a fixed number of shares of common stock of the Company calculated as the principal amount of each convertible note divided by $11.3750 (reflecting 100% warrant coverage). The warrants did not have any cashless exercise provisions and, when issued, were exercisable through September 30, 2015 at a fixed price of $11.3750 per share. The shares of common stock issuable upon conversion of the notes payable and the exercise of the warrants were not subject to any registration rights. In the same offering, on December 9, 2014, December 31, 2014, and February 2, 2015, the Company sold an additional $46,000, $85,000 and $210,000, respectively, of principal amount of the convertible notes and warrants to various accredited investors. The Company terminated this financing effective February 18, 2015, which had generated aggregate gross proceeds of $579,500, and in connection with which the Company had issued warrants to purchase 50,945 shares of common stock. The closing market prices of the Company’s common stock on the transaction closing dates of November 5, 2014, December 9, 2014, December 31, 2014 and February 2, 2015 were $17.0300 per share, $13.3575 per share, $14.6575 per share and $13.9750 per share, respectively, as compared to the fixed conversion price of the convertible notes and the fixed exercise price of the warrants of $11.3750 per share. Accordingly, the Company has accounted for the beneficial conversion features with respect to the sale of the convertible notes and the issuance of the warrants in accordance with Accounting Standards Codification Topic (ASC) 470-20, Accounting for Debt with Conversion and Other Options. The Company considered the face value of the convertible notes to be representative of their fair value. The Company determined the fair value of the warrants based on the Black-Scholes option-pricing model. The relative fair value method generated respective fair values for each of the convertible notes and the warrants of approximately 50% for the convertible notes and approximately 50% for the warrants sold with the convertible notes. Once these values were determined, the fair value of the warrants of $289,106 and the fair value of the beneficial conversion feature of $290,394 (which were calculated based on the effective conversion price) were recorded as a reduction to the face value of the promissory note obligation. As a result, this aggregate debt discount reduced the carrying value of the convertible notes to zero at each issuance date. The excess amount generated from this calculation was not recorded, as the carrying value of a promissory note cannot be reduced below zero. The aggregate debt discount was amortized as interest expense over the original term of the promissory notes. The difference between the amortization of the debt discount calculated based on the straight-line method and the effective yield method was not material. The cash fees paid to placement agents and for legal costs incurred from November 5, 2014 through February 2, 2015 with respect to this financing were deferred and capitalized as deferred offering costs and were amortized to interest expense over the original term of the convertible notes through September 15, 2015 on the straight-line method. The placement agent warrants were considered as an additional cost of the offering and were included in deferred offering costs at fair value. The difference between the amortization of the deferred offering costs calculated based on the straight-line method and the effective yield method was not material. Extension of Notes and Original Warrants, and Issuance of New Warrants On August 13, 2015, pursuant to the terms of the convertible notes, the Company elected to extend the maturity date of the convertible notes to September 15, 2016. Under the terms of the convertible notes, the Company was required to issue to note holders 27,396 additional warrants (the “New Warrants”) that were exercisable through September 15, 2016. The New Warrants were exercisable for that number of shares of common stock of the Company calculated as the principal amount of the convertible notes (an aggregate amount of $579,500), plus any accrued and unpaid interest (an aggregate amount of $43,758), multiplied by 50%, and then divided by $11.3750. The New Warrants otherwise had terms substantially similar to the 50,945 original warrants issued to the investors. In connection with the extension of the maturity date of the convertible notes, the Board of Directors of the Company also determined to extend the termination date of the 50,945 original warrants to September 15, 2016, so that they were coterminous with the new maturity date of the convertible notes. The Company reviewed the guidance in ASC 405-20, Extinguishment of Liabilities, and determined that the convertible notes had not been extinguished. The Company therefore concluded that the guidance in ASC 470-50, Modifications and Extinguishments, should be applied, which states that if the exchange or modification is not to be accounted for in the same manner as a debt extinguishment, then the fees shall be associated with the replacement or modified debt instrument and, along with any existing unamortized premium or discount, amortized as an adjustment of interest expense over the remaining term of the replacement or modified debt instrument using the interest method. The Company deferred the debt modification costs related to the modification of the convertible notes and the issuance of the New Warrants (consisting of the fair value of the New Warrants) over the remaining term of the extended notes. The Company accounted for such costs as a discount to the convertible notes and amortized such costs to interest expense over the extended term of the convertible notes on the straight-line method. The difference between the amortization of these costs calculated based on the straight-line method and the effective yield method was not material. The Company deferred the debt modification costs related to the extension of the original warrants (consisting of the fair value of the extension of the original warrants) over the remaining term of the extended convertible notes. The Company accounted for such costs as a discount to the convertible notes and amortized such costs to interest expense over the extended term of the convertible notes on the straight-line method. The difference between the amortization of these costs calculated based on the straight-line method and the effective yield method was not material. The closing market price of the Company’s common stock on the extension date of September 15, 2015 was $10.0750 per share, as compared to the fixed conversion price of the convertible notes and the fixed exercise price of both the original warrants and the New Warrants of $11.3750 per share. The Company accounted for the beneficial conversion features with respect to the extension of the convertible notes and the extension of the original warrants and the issuance of the New Warrants in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company considered the face value of the convertible notes, plus the accrued interest thereon, to be representative of their fair value. The Company determined the fair value of the 27,396 New Warrants and the fair value of extending the 50,945 original warrants based on the Black-Scholes option-pricing model. The relative fair value method generated respective fair values for each of the convertible notes, including accrued interest, and the New Warrants and extension of the original warrants, of approximately 55% for the convertible notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original warrants. Once these values were determined, the fair value of the New Warrants and extension of the original warrants of $277,918 and the fair value of the beneficial conversion feature of $206,689 (which were calculated based on the effective conversion price) were recorded as a reduction to the face value of the promissory note obligation. The aggregate debt discount was amortized as interest expense over the extended term of the promissory notes. The difference between the amortization of the debt discount calculated based on the straight-line method and the effective yield method was not material. Note Exchange Agreements During April and May 2016, the Company entered into Note Exchange Agreements with certain note holders, including one non-officer/director affiliate, as described below, representing an aggregate of $303,500 of principal amount of the convertible notes (out of a total of $579,500 of original principal amount of the convertible notes payable). The Note Exchange Agreements were substantially similar, and provided for the note holders to exchange their notes, original warrants and New Warrants (collectively, the “Exchanged Securities”), plus cash, in exchange for shares of the Company’s common stock. In the aggregate, $344,483 of principal amount and accrued interest of the convertible notes, original warrants to purchase 26,681 shares of the Company’s common stock and New Warrants to purchase 14,259 shares of the Company’s common stock, plus an aggregate of $232,846 in cash, were exchanged for 101,508 shares of the Company’s common stock, with a total market value of $631,023 (average $6.2075 per share), which resulted in a credit to total stockholders’ deficiency of $577,329. All of the Exchanged Securities were cancelled as a result of the respective exchange transactions. Among the executed Note Exchange Agreements, the Company entered into one Note Exchange Agreement with a non-officer/director affiliate effective May 4, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which this affiliate exchanged $28,498 of principal amount and accrued interest of the convertible notes, original warrants to purchase 2,198 shares of the Company’s common stock and New Warrants to purchase 1,178 shares of the Company’s common stock, plus $19,200 in cash, in return for 8,386 shares of the Company’s common stock. This transaction was treated as though the exchanging note holders agreed to exchange their convertible notes (including accrued interest) into common stock at a 50% discount to the conversion rate ($11.3750 per share) provided for by the terms of the convertible notes, if they also exchanged all of their warrants associated with the convertible notes, plus paid cash equal to a 50% discount to the exercise price ($11.3750 per share). For accounting purposes, the transactions have been treated as if (i) the participants had converted the convertible notes (which included accrued but unpaid interest of $40,993) at a conversion price reduced from $11.3750 to $5.6875 per share, and that such conversions in the aggregate resulted in the issuance of an aggregate of 60,568 shares of common stock, and (ii) the participants had exercised their original warrants to purchase an aggregate of 26,681 shares of common stock and the New Warrants to purchase an aggregate of 14,259 shares of common stock, all at an exercise price reduced from $11.3750 to $5.6875 per share, and that such exercise of the warrants generated an aggregate cash payment to the Company of $232,846 and resulted in the issuance of an aggregate of 40,940 shares of common stock. In connection with the exchange of the convertible notes, original warrants, New Warrants and the payment of cash, a total of 101,508 shares of common stock in the aggregate were issued. The closing market price of the Company’s common stock during the period that these exchange transactions were entered into ranged from $5.8500 to $7.7675 per share. The Company reviewed the guidance in ASC 470-20-40-13 through 17, Recognition of Expense Upon Conversion, and in ASC 470-20-40-26, Induced Conversions. Pursuant to this accounting guidance, for those convertible note holders accepting the Company’s exchange offer, the Company evaluated the fair value of the incremental consideration paid to induce the convertible note holders to exchange their convertible notes for equity (i.e., 30,284 shares of common stock), based on the closing market price of the Company’s common stock on the date of each transaction, and recorded a charge to operations of $188,274. The Company evaluated the warrants exchanged in conjunction with the Note Exchange Agreements. The Company calculated the fair value of the warrants exchanged (consisting of the warrants issued in conjunction with the original issuance of the convertible notes) as if the warrants were modified immediately before the theoretical warrant modification and immediately after such warrant modification. As the fair value of the warrants immediately after the modifications was less than the fair value of the warrants immediately before the modifications (both amounts calculated pursuant to the Black-Scholes option-pricing model), the Company did not record any accounting entry with respect to the warrant exchange transactions. The fair value of the warrants subject to the Note Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 11.3750 $ 5.6875 Stock price $5.8500 to $7.5400 $5.8500 to $7.5400 Risk-free interest rate 0.23 % 0.23 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 months 0 months 2015 Unit Offering Units sold to investors on August 28, 2015, September 28, 2015 and November 2, 2015 were comprised of one share of the Company’s common stock and one common stock purchase warrant to purchase two additional shares of the Company’s common stock. Units were sold for $6.83475 per unit and the warrants issued in connection with the units were exercisable at a fixed price $6.83475 per share of the Company’s common stock. The warrants provided no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this unit financing. The aggregate gross proceeds of this unit financing was $1,194,710. Unit Exchange Agreements During April and May 2016, the Company entered into Unit Exchange Agreements with certain warrant holders, including two affiliates, one of whom was Dr. Manuso, and the other of whom was a non-officer/director affiliate, both as described below. The Unit Exchange Agreements were substantially similar, and provided for the warrant holders to exchange (i) existing warrants to purchase an aggregate of 217,188 shares of the Company’s common stock (which were cancelled as a result of the respective exchange transactions), plus (ii) an aggregate of $529,394 in cash, in return for (i) an aggregate of 108,594 shares of the Company’s common stock, and (ii) new warrants to purchase an aggregate of 108,594 shares of the Company’s common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. Among the executed Unit Exchange Agreements, the Company entered into a Unit Exchange Agreement with Dr. Manuso effective April 6, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which Dr. Manuso exchanged a warrant to purchase 73,156 shares of the Company’s common stock that was originally issued to him in the Company’s August 28, 2015 unit offering (which was cancelled as a result of the exchange transaction), plus $178,317 in cash, in return for 36,578 shares of the Company’s common stock and the issuance of a new warrant to purchase 36,578 shares of the Company’s common stock. The new warrant has the same expiration date as the original warrant (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. The closing market price of the Company’s common stock on April 6, 2016 was $7.7675 per share. Among the executed Unit Exchange Agreements, the Company also entered into Unit Exchange Agreements (which are included in the summary paragraph above) with a non-officer/director affiliate (and his affiliate) effective May 4, 2016 (the financial information with respect thereto is included in the summary paragraph presented above), pursuant to which this affiliate exchanged warrants to purchase 88,132 shares of the Company’s common stock that were originally issued to the affiliate in the Company’s August 28, 2015 unit offering (which were cancelled as a result of the exchange transaction), plus $214,822 in cash, in return for 44,066 shares of the Company’s common stock and the issuance of new warrants to purchase 44,066 shares of the Company’s common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. The closing market price of the Company’s common stock on May 4, 2016 was $5.8500 per share. This transaction was treated as though exchanging warrant holders who received their warrants in any of the three closings of the Company’s 2015 unit offering agreed to exchange their warrants associated with such financing, plus paid cash equal to a reduced exercise price per share ($4.8750 per share) for 50% of such warrants, with 50% of the warrants replaced with similar warrants with the same term at a reduced exercise price. For accounting purposes, the transactions have been treated as if (i) participants exercised one-half of the existing warrants entitling them to purchase an aggregate of 217,188 shares of the Company’s common stock that were originally issued to them in the Company’s unit offering, with closings on August 28, 2015, September 28, 2015 and November 2, 2015 (i.e., warrants to purchase 108,594 shares of common stock), at an exercise price reduced from $6.8348 to $4.8750 per share, and (ii) the other one-half of the original warrants were cancelled. The Unit Exchange Agreements also provided for the Company to issue new warrants to the participants to purchase an aggregate of 108,594 shares of common stock. The new warrants have the same expiration date as the original warrants (September 30, 2020) and may be exercised for cash or on a cashless basis at $4.8750 per share. For accounting purposes, the transaction was treated as if the warrant exercise price for all of the warrants was reduced from $6.8348 to $4.8750 per share, in exchange for which 50% of the warrants were exercised for cash at the reduced exercise price, and the remaining 50% of the warrants continued to remain outstanding through September 30, 2020 and gained a cashless exercise provision. The closing market price of the Company’s common stock during the period that these exchange transactions were entered into ranged from $5.8500 to $7.7675 per share. The Company evaluated the warrants exchanged in conjunction with the Unit Exchange Agreements. The Company calculated the fair value of the warrants exchanged as if the warrants were modified immediately before the theoretical warrant modification and immediately after such warrant modification. As the fair value of the warrants immediately after the modifications was less than the fair value of the warrants immediately before the modifications (both amounts calculated pursuant to the Black-Scholes option-pricing model), the Company did not record any accounting entry with respect to the warrant exchange transactions. The fair value of the warrants subject to the Unit Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 6.8348 $ 4.8750 Stock price $5.8500 to $7.7675 $5.8500 to $7.7675 Risk-free interest rate 1.12 % 0.23 % and 1.12 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 years 0 years to 4.5 years 1 st Units were sold to investors from January 8, 2016 through June 30, 2016 (the “1 st The closing market prices of the Company’s common stock on the transaction closing dates from January 8, 2016 through June 30, 2016, ranged from a low of $3.4416 on February 9, 2016 to a high of $9.7403 on February 29, 2016. 2 nd On December 29, 2016 and December 30, 2016, the Company sold units to investors for aggregate gross proceeds of $185,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (the “2 nd nd nd The closing market prices of the Company’s common stock on December 29, 2016 and December 30, 2016 were $2.85 and $2.80 respectively. 1 st On March 10, 2017 and March 28, 2017, the Company sold units to investors for aggregate gross proceeds of $350,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (the “1 st nd st On July 26, 2017, the Company’s Board approved an offering of securities conducted via private placement (the “2 nd nd st st nd st nd nd 2 nd On August 29, 2017, September 27, 2017, September 28, 2017, October 5, 2017 and October 25, 2017, the Company sold units to investors for aggregate gross proceeds of $157,000, with each unit consisting of one share of the Company’s common stock and one common stock purchase warrant to purchase one share of the Company’s common stock (2 nd nd nd nd The terms of the 2 nd st st nd nd
Equipment	Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years.
Long-Term Prepaid Insurance	Long-Term Prepaid Insurance Long-term prepaid insurance represents the premium paid in June 2017 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve-month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2017.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in the Company’s financial statements ratably over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Board members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Board and to outside consultants are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, the risk-free interest rate and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. For stock options requiring an assessment of value during the nine months ended September 30, 2017, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 1.83% to 1.92 % Expected dividend yield 0 % Expected volatility 132.87 % Expected life 4.833 years For stock options requiring an assessment of value during the nine months ended September 30, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 0.87% to 1.31 % Expected dividend yield 0 % Expected volatility 181.76% to 202.51 % Expected life 3.9 to 5 years The Company recognizes the fair value of stock-based compensation in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the nine months ended September 30, 2017 and 2016.
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2017, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2017, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Foreign Currency Transactions	Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research Grants	Research Grants The Company recognizes revenues from research grants as earned based on the percentage-of-completion method of accounting and issues invoices for contract amounts billed based on the terms of the grant agreement. Amounts recorded under research grants in excess of amounts earned are classified as unearned grant revenue liability in the Company’s condensed consolidated balance sheet. Research grants are generally funded and paid through government or institutional programs. Amounts received under research grants are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance with the approved grant project. The Company had no research grant revenue during the nine months ended September 30, 2017 and 2016. At September 30, 2017 and 2016, the Company did not have any grants receivable or unearned grant revenues.
Research and Development	Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), patent fees and costs, and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At September 30, 2017, a balance of $48,912 remained from the advance payment.
License Agreements	License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the nine months ended September, 2017 and 2016.
Earnings Per Share	Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2017 and 2016, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September, 2017 2016 Series B convertible preferred stock 11 11 Convertible notes payable 32,239 29,057 Common stock warrants 985,915 409,914 Common stock options 2,046,749 1,307,749 Total 3,064,914 1,746,731
Reclassifications	Reclassifications Certain comparative figures in 2017 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In May 2017, the FASB issued Accounting Standards Update No. 2017-09 (ASU 2017-09), Compensation – Stock Compensation (Topic 718) Scope of Modification Accounting. The amendments in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The adoption of ASU 2017-09, which will become effective for annual periods beginning after December 15, 2017 and for interim periods within those annual periods, is not expected to have any impact on the Company’s financial statement presentation or disclosures. In July 2017, the FASB issued Accounting Standards Update No. 2017-11 (ASU 2017-11), Earnings Per Share (Topic 260): Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815) – I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. The amendments in ASU 2017-11 address the complexity of accounting for certain financial instruments with down round features. The amendments, when effective or earlier applied, provide that down round feature would no longer preclude equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The amendments also provide that as of the date that a down round feature is triggered (that is, upon the occurrence of the triggering event that results in a reduction of the strike price) in an equity-classified freestanding financial instrument, an entity shall measure the value of the effect of the feature as the difference between the following amounts determined immediately after the down round feature is triggered: 1. the fair value of the financial instrument (without the down round feature) with a strike price corresponding to the currently stated strike price of the issued instrument (that is, before the strike price reduction), and 2. the fair value of the financial instrument (without the down round feature) with a strike price corresponding to the reduced strike price upon the down round feature being triggered. Part II of the update addresses mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests with a scope exception. The amendments in Part II do not have an accounting effect and address the indefinite deferral of certain guidance in Topic 480 with a scope exception with the intent of improving the readability of the Codification and reducing the complexity associated with navigating Topic 480. The amendments in Part I of the update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of ASU 2017-11 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In August 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2017-12 —Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard is intended to improve and simplify accounting rules around hedge accounting. The new standard refines and expands hedge accounting for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes, for investors and analysts. The new standard takes effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, for public companies and for fiscal years beginning after December 15, 2019 (and interim periods for fiscal years beginning after December 15, 2020), for private companies. Early adoption is permitted in any interim period or fiscal years before the effective date of the standard. The adoption of ASU 2017-12 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Fair Value of Warrants Estimated Using Black-Scholes Pricing Model with Valuation Assumptions	The fair value of the warrants subject to the Note Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 11.3750 $ 5.6875 Stock price $5.8500 to $7.5400 $5.8500 to $7.5400 Risk-free interest rate 0.23 % 0.23 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 months 0 months
Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions	The fair value of the warrants subject to the Unit Exchange Agreements was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: Before Warrant Modifications After Warrant Modifications Exercise price per warrant $ 6.8348 $ 4.8750 Stock price $5.8500 to $7.7675 $5.8500 to $7.7675 Risk-free interest rate 1.12 % 0.23 % and 1.12 % Expected dividend yield 0 % 0 % Expected volatility 201.59 % 201.59 % Expected life 4.4 to 4.5 years 0 years to 4.5 years For stock options requiring an assessment of value during the nine months ended September 30, 2017, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 1.83% to 1.92 % Expected dividend yield 0 % Expected volatility 132.87 % Expected life 4.833 years For stock options requiring an assessment of value during the nine months ended September 30, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 0.87% to 1.31 % Expected dividend yield 0 % Expected volatility 181.76% to 202.51 % Expected life 3.9 to 5 years
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	September, 2017 2016 Series B convertible preferred stock 11 11 Convertible notes payable 32,239 29,057 Common stock warrants 985,915 409,914 Common stock options 2,046,749 1,307,749 Total 3,064,914 1,746,731

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Notes Payable	The Notes (including those placed in default as described above) consist of the following at September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Principal amount of notes payable $ 276,000 $ 276,000 Add accrued interest payable 90,667 62,616 $ 366,667 $ 338,616
Summary of Note Payable to Related Party	Note payable to SY Corporation consists of the following at September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 255,243 219,362 Foreign currency translation adjustment 5,599 (25,129 ) $ 660,616 $ 594,007

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the nine months ended September 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2016 540,198 $ 4.84842 Issued 445,717 1.36478 Warrants outstanding at September 30, 2017 985,915 $ 3.27352 4.7567 Warrants exercisable at December 31, 2016 540,198 $ 4.84842 Warrants exercisable at September 30, 2017 985,915 $ 3.27352 4.7567 A summary of warrant activity for the nine months ended September 30, 2016 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2015 482,288 $ 7.10125 Issued, net of exercises and expirations (72,374 ) $ (1.03629 ) Warrants outstanding at September 30, 2016 409,914 $ 5.89296 3.84 Warrants exercisable at December 31, 2015 482,288 $ 7.10125 Warrants exercisable at September 30, 2016 409,914 $ 5.89296 3.84
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2017: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 0 0 December 31, 2021 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,005 86,005 February 28, 2021 $ 2.7500 108,000 108,000 December 31, 2021 $ 1.1000 468,000 468,000 September 29, 2022 985,915 985,915 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2016: Exercise Price Warrants Outstanding (Shares) Warrants Exercisable (Shares) Expiration Date $ 1,2870 41,002 41,002 April 17, 2019 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 409,914 409,914
Schedule of Stock Options Activity	A summary of stock option activity for the nine months ended September 30, 2017 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2016 1,307,749 $ 7.6515 Granted 739,000 Options outstanding at September 30, 2017 2,046,749 $ 6.0125 4.54 Options exercisable at December 31, 2016 1,307,749 $ 7.6515 Options exercisable at September 30, 2017 2,019,249 $ 6.0125 4.54 A summary of stock option activity for the nine months ended September 30, 2016 is presented below. Number of Shares Weighted Average Exercise Price Weighted Remaining Contractual Life (in Years) Options outstanding at December 31, 2015 774,842 $ 7.8325 Granted 532,907 7.3305 Options outstanding at September 30, 2016 1,307,749 $ 7.6241 5.56 Options exercisable at December 31, 2015 519,662 $ 8.5150 Options exercisable at September 30, 2016 1,177,364 $ 7.6515 5.68
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2017: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 1.3500 34,000 19,000 July 28, 2022 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 12,500 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 2,046,749 2,019,249 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2016: Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 4.500 7,222 7,222 September 2, 2021 $ 5.7500 2,608 2,608 September 12, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 392,692 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.2500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.500 6,410 6,410 August 10, 2022 1,307,749 1,177,364

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Principal Cash Obligations and Commitments	Payments Due By Year Total 2017 2018 2019 2020 2021 Research and development contracts $ — $ — $ — $ — $ — $ — Clinical trial agreements — — — — — — License agreements 425,000 25,000 100,000 100,000 100,000 100,000 Employment and consulting agreements (1) 1,093,800 273,450 820,350 — — — Total $ 1,518,800 $ 298,450 $ 920,350 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements”.

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($)	Aug. 16, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Common stock, par value		$ 0.001		$ 0.001		$ 0.001
Common stock, shares authorized		65,000,000		65,000,000		65,000,000
Preferred stock designated		5,000,000		5,000,000		5,000,000
Preferred stock, per share		$ 0.001		$ 0.001		$ 0.001
Percentage of acquired merger issued and outstanding equity securities				100.00%
Net losses		$ 618,542	$ 2,391,802	$ 3,671,753	$ 7,804,002	$ 9,229,760
Negative operating cash flows				495,817	$ 1,212,331	1,328,684
Total stockholders' deficiency		$ 6,766,304		6,766,304		$ 5,493,377
PACE Trial [Member]
Fund granted , value				$ 5,000,000
Board of Directors [Member]
Reverse stock split	325 to 1 reverse stock split
Common stock, par value	$ 0.001
Capital stock, authorized	70,000,000
Common stock, shares authorized	65,000,000
Preferred stock designated	5,000,000
Preferred stock, per share	$ 0.001
Board of Directors [Member] | Amendment [Member]
Reverse stock split	Pursuant to the amendment, an aggregate of 191.068 fractional shares resulting from the reverse stock split were not issued, but were to be paid out in cash (without interest or deduction) in an amount equal to the number of shares exchanged into such fractional share multiplied by the average closing trading price of the Company’s common stock on the OTCQB for the five trading days immediately before the Certificate of Amendment effecting the reverse stock split was filed with the Delaware Secretary of State ($6.7899 per share, on a post reverse stock split basis) for an aggregate of $1,298.
Fractional shares resulting from reverse stock split	191.068
Reverse stock split per share	$ 6.7899
Total value of Reverse stock split	$ 1,298

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Oct. 25, 2017	Oct. 05, 2017	Sep. 28, 2017	Sep. 27, 2017	Aug. 29, 2017	Mar. 28, 2017	Mar. 10, 2017	Dec. 30, 2016	Dec. 29, 2016	Sep. 15, 2016	May 04, 2016	Aug. 13, 2015	Feb. 18, 2015	Feb. 02, 2015	Dec. 31, 2014	Dec. 31, 2014	Dec. 09, 2014	Nov. 05, 2014	May 31, 2016	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 27, 2017	Sep. 30, 2016	Apr. 06, 2016	Feb. 29, 2016	Feb. 09, 2016	Sep. 15, 2015	Aug. 10, 2012
Number of original warrants issued during period										13,137										24,264
Fixed exercise price of old and new warrants																				$ 11.3750	$ 0.035
Total stockholders' deficiency																				$ (6,766,304)	$ (5,493,377)
Convertible preferred stock, per share																								$ 5.85
Common stock, shares issued																				2,586,761	2,149,045
Common stock, price per share at closing dates																														$ 18.2000
Cumulative change in ownership percentage																				50.00%
2015 Unit Offering [Member]
Gross proceeds																				$ 1,194,710
Fixed exercise price of old and new warrants																				$ 6.83475
Common stock, price per share at closing dates																				$ 6.83475
2015 unit offering Costs [Member]
Fair value of warrants, percentage																				50.00%
Warrant to purchase shares																				217,188
1st 2016 Unit Offering [Member]
Gross proceeds																				$ 307,985
Fixed exercise price of old and new warrants																				$ 7.93
Common stock, price per share at closing dates																				$ 7.2085							$ 9.7403	$ 3.4416
Percentage of investor beneficially outstanding shares of common stock																				4.99%
2nd 2016 Unit Offering [Member]
Convertible into common stock fixed price per share								$ 0.001	$ 0.001
Gross proceeds								$ 185,000	$ 185,000
Fixed exercise price of old and new warrants								$ 2.80	$ 2.85											$ 1.562
Common stock, price per share at closing dates																				$ 1.42
Percentage of investor beneficially outstanding shares of common stock																				4.99%
Percentage of unit purchase price																				200.00%
1st 2017 Unit Offering [Member] | Placement Agent [Member]
Common stock warrant for cash																				$ 27,648
Cash placement agent fees																				$ 20,000
Number of warrant shares fee																				8,000
1st 2017 Unit Offering [Member] | Investors [Member]
Convertible into common stock fixed price per share						$ 0.001	$ 0.001
Gross proceeds						$ 350,000	$ 350,000
Fixed exercise price of old and new warrants						$ 2.75	$ 2.75
Common stock fixed price per share						2.50	2.50
Common stock, price per share at closing dates						$ 3.80	$ 4.05
Percentage of investor beneficially outstanding shares of common stock						4.99%	4.99%
Percentage of unit purchase price						200.00%	200.00%
2nd 2017 Unit Offering [Member] | Investors [Member]
Convertible into common stock fixed price per share	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Gross proceeds	$ 157,000	$ 157,000	$ 157,000	$ 157,000	$ 157,000
Fixed exercise price of old and new warrants	$ 1.10	$ 1.10	$ 1.10	$ 1.10	$ 1.10
Common stock fixed price per share	1	1	1	1	1
Common stock, price per share at closing dates	$ .80	$ 1.50	$ 1.40	$ 1.40	$ 1
Percentage of investor beneficially outstanding shares of common stock			4.99%	4.99%	4.99%
Percentage of unit purchase price			250.00%	250.00%	250.00%
Minimum [Member]
Estimated useful lives																				3 years
Minimum [Member] | 2015 unit offering Costs [Member]
Debt conversion price per share																				$ 6.8348
Fixed exercise price of old and new warrants																				6.8348
Common stock fixed price per share																				$ 5.8500
Maximum [Member]
Estimated useful lives																				5 years
Maximum [Member] | 2015 unit offering Costs [Member]
Debt conversion price per share																				$ 4.8750
Fixed exercise price of old and new warrants																				4.8750
Common stock fixed price per share																				7.7675
Warrants [Member]
Debt instrument due date												Sep. 15, 2016
Debt conversion price per share																				$ 11.3750
Number of extension warrants issued during period												27,396
Fair value of convertible notes, percentage																				50.00%
Fair value of warrants																				$ 289,106
Fair value of beneficial conversion feature value												$ 206,689								$ 290,394
Convertible notes principal amount												579,500
Accrued and unpaid interest												$ 43,758
Percentage of unpaid interest multiplied												50.00%
Dividend price per share												$ 11.3750
Number of original warrants issued during period												50,945
Number of new extensive warrants issued												27,396
Convertible debt original principal amount												$ 579,500
Warrants extension, description												The New Warrants and extension of the original Warrants, of approximately 55% for the Notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original Warrants.
Fair value of new warrants and extension of old warrants												$ 277,918
Old Warrants [Member]
Number of original warrants issued during period										50,945
Original Warrants [Member]
Fixed exercise price of old and new warrants																													$ 10.0750
New Warrants [Member]
Fixed exercise price of old and new warrants																													$ 11.3750
Closing Market Price [Member]
Debt conversion price per share														$ 13.9750	$ 14.6575	$ 14.6575	$ 13.3575	$ 17.0300					$ 14.6575
Convertible Notes Payable [Member]
Proceeds from issuance of private placements															$ 85,000
New Warrants [Member] | 2015 unit offering Costs [Member]
Fixed exercise price of old and new warrants																				$ 4.8750
Warrant to purchase shares																				108,594
Warrants expiration date																				Sep. 30, 2020
Original Warrants [Member] | 2015 unit offering Costs [Member]
Warrant to purchase shares																				108,594
Common stock fixed price per share																				$ 4.8750
Note Exchange Agreements [Member]
Percentage of convertible notes payable											50.00%								10.00%
Debt conversion price per share											$ 11.3750
Fair value of beneficial conversion feature value																					$ 49,688
Convertible notes principal amount											$ 28,498								$ 303,500
Accrued and unpaid interest																				$ 40,993
Convertible debt original principal amount																			579,500
Warrant to purchase shares																				40,940
Common stock warrant for cash											$ 19,200								$ 232,846	$ 232,846
Number of common stock shares exchanged for note during the period											8,386								101,508	60,568
Number of common stock shares exchanged for note of market value																			$ 631,023
Note Exchange Agreements [Member] | Minimum [Member]
Debt conversion price per share																				$ 11.3750
Note Exchange Agreements [Member] | Maximum [Member]
Debt conversion price per share																				$ 5.6875
Note Exchange Agreements [Member] | Original Warrants [Member]
Warrant to purchase shares											2,198								26,681
Note Exchange Agreements [Member] | New Warrants [Member]
Percentage of convertible notes payable											50.00%
Debt conversion price per share											$ 11.3750
Convertible notes principal amount																			$ 344,483
Warrant to purchase shares											1,178								14,259
Common stock exchange average price per share																			$ 6.2075
Total stockholders' deficiency																			$ 577,329
Common stock, shares issued																			30,284
Note exchange inducement cost																				$ 188,274
Note Exchange Agreements [Member] | New Warrants [Member] | Minimum [Member]
Convertible preferred stock, per share																			$ 5.8500
Note Exchange Agreements [Member] | New Warrants [Member] | Maximum [Member]
Convertible preferred stock, per share																			$ 7.7675
Note Exchange Agreements [Member] | New Warrants [Member]
Warrant to purchase shares																				26,681
Note Exchange Agreements [Member] | Original Warrants [Member]
Warrant to purchase shares																				14,259
Unit Exchange Agreements [Member] | New Warrants [Member]
Fixed exercise price of old and new warrants																				$ 4.8750
Number of shares return during peirod																				36,578
Warrants expiration date																				Sep. 30, 2020
Unit Exchange Agreements [Member] | New Warrants 1 [Member]
Fixed exercise price of old and new warrants																				$ 4.8750
Warrants expiration date																				Sep. 30, 2020
Unit Exchange Agreements [Member] | New Warrants 2 [Member]
Fixed exercise price of old and new warrants																				$ 4.8750
Warrants expiration date																				Sep. 30, 2020
Subsequent Financings Aggregate [Member] | December 30, 2017 [Member] | 2nd 2016 Unit Offering [Member]
Gross proceeds																				$ 15,000,000
Subsequent Financings Aggregate [Member] | December 30, 2017 [Member] | 1st 2017 Unit Offering [Member]
Gross proceeds																				15,000,000
Subsequent Financings Aggregate [Member] | December 30, 2017 [Member] | 2nd 2017 Unit Offering [Member]
Gross proceeds																				15,000,000
Duke University [Member]
Advance payment																				48,912
Purchaser [Member] | Warrant Purchase Agreement [Member]
Proceeds from issuance convertible notes payable																		$ 238,500
Debt instrument due date																		Sep. 15, 2015
Percentage of warrants coverage																		100.00%
Investors [Member] | Warrant Purchase Agreement [Member]
Debt conversion price per share																		$ 11.3750
Two Affiliates [Member] | Unit Exchange Agreements [Member]
Warrant to purchase shares																			217,188
Common stock warrant for cash																			$ 529,394
Common stock, shares issued																			108,594
Two Affiliates [Member] | Unit Exchange Agreements [Member] | New Warrants [Member]
Warrant to purchase shares																			108,594
Dr. Manuso [Member] | Unit Exchange Agreements [Member]
Warrant to purchase shares																										73,156
Common stock warrant for cash																										$ 178,317
Dr. Manuso [Member] | Unit Exchange Agreements [Member] | New Warrants [Member]
Warrant to purchase shares																										36,578
Convertible preferred stock, per share																										$ 7.7675
Non-Officer/Director Affiliate [Member] | Unit Exchange Agreements [Member]
Fixed exercise price of old and new warrants											$ 5.8500
Warrant to purchase shares											88,132
Non-Officer/Director Affiliate [Member] | Unit Exchange Agreements [Member] | New Warrants [Member]
Warrant to purchase shares											44,066
Common stock warrant for cash											$ 214,822
Number of common stock shares exchanged for note during the period											44,066
Convertible Notes Payable [Member] | Investors [Member]
Percentage of convertible notes payable															10.00%	10.00%						10.00%	10.00%
Convertible into common stock fixed price per share																						$ 11.3750	$ 11.3750
Convertible Notes Payable [Member]
Proceeds from issuance of private placements														$ 210,000		$ 85,000	$ 46,000
Gross proceeds													$ 579,500
Number of extension warrants issued during period													50,945
Accrued and unpaid interest																									$ 40,983
Number of common stock shares exchanged for note during the period																					29,768

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Summary of Fair Value of Warrants Estimated Using Black-Scholes Pricing Model With Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2017$ / shares
Note Exchange Agreements [Member] | Before Warrant Modifications [Member]
Exercise price per warrant	$ 11.3750
Note Exchange Agreements [Member] | Before Warrant Modifications [Member]
Risk-free interest rate	0.23%
Expected dividend yield	0.00%
Expected volatility	201.59%
Note Exchange Agreements [Member] | Before Warrant Modifications [Member] | Minimum [Member]
Stock price	$ 5.8500
Expected life	4 years 4 months 24 days
Note Exchange Agreements [Member] | Before Warrant Modifications [Member] | Maximum [Member]
Stock price	$ 7.5400
Expected life	4 years 5 months 12 days
Note Exchange Agreements [Member] | After Warrant Modifications [Member]
Exercise price per warrant	$ 5.6875
Risk-free interest rate	0.23%
Expected dividend yield	0.00%
Expected volatility	201.59%
Expected life	0 months
Note Exchange Agreements [Member] | After Warrant Modifications [Member] | Minimum [Member]
Stock price	$ 5.8500
Note Exchange Agreements [Member] | After Warrant Modifications [Member] | Maximum [Member]
Stock price	7.5400
Unit Exchange Agreements [Member] | Before Warrant Modifications [Member]
Exercise price per warrant	$ 6.8348
Risk-free interest rate	1.12%
Expected dividend yield	0.00%
Expected volatility	201.59%
Unit Exchange Agreements [Member] | Before Warrant Modifications [Member] | Minimum [Member]
Stock price	$ 5.8500
Expected life	4 years 4 months 24 days
Unit Exchange Agreements [Member] | Before Warrant Modifications [Member] | Maximum [Member]
Stock price	$ 7.7675
Expected life	4 years 6 months
Unit Exchange Agreements [Member] | After Warrant Modifications [Member]
Exercise price per warrant	$ 4.8750
Expected dividend yield	0.00%
Expected volatility	201.59%
Unit Exchange Agreements [Member] | After Warrant Modifications [Member] | Minimum [Member]
Stock price	$ 5.8500
Risk-free interest rate	0.23%
Expected life	0 years
Unit Exchange Agreements [Member] | After Warrant Modifications [Member] | Maximum [Member]
Stock price	$ 7.7675
Risk-free interest rate	1.12%
Expected life	4 years 6 months

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected dividend yield	0.00%	0.00%
Expected volatility	132.87%
Expected life	4 years 99 months 29 days
Minimum [Member]
Risk-free interest rate	1.83%	0.87%
Expected volatility		181.76%
Expected life		3 years 10 months 25 days
Maximum [Member]
Risk-free interest rate	1.92%	1.31%
Expected volatility		202.51%
Expected life		5 years

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share	3,064,914	1,746,731
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	11	11
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	32,239	29,057
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	985,915	409,914
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	2,046,749	1,307,749

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 27, 2017	Sep. 23, 2016	Sep. 22, 2016	Sep. 15, 2016	May 04, 2016	Feb. 02, 2016	Jan. 29, 2016	Aug. 13, 2015	Feb. 18, 2015	Feb. 02, 2015	Dec. 31, 2014	Dec. 09, 2014	Nov. 05, 2014	May 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Sep. 15, 2015	Jun. 25, 2013	Jun. 25, 2012
Percentage of convertible notes payable				12.00%											10.00%		10.00%
Note automatically convert into common stock equivalent price															$ 11.3750		$ 11.3750
Warrants exercise price per share															$ 11.3750		$ 11.3750		$ 0.035
Warrants originally exercisable fixed price per share																				$ 11.3750
Accrued interest payable				$ 53,261											$ 21,305		$ 21,305
Number of original warrants issued during period				13,137													24,264
Secured note payable value				$ 329,261											82,305		$ 82,305
Common shares issuable in private placement	16,453
Interest expense															26,354	$ 115,847	77,674	$ 562,053
Stockholder's percentage																					20.00%
Note Exchange Agreements [Member]
Proceeds from issuance of private placements														$ 303,500
Convertible debt original principal amount														579,500
Common stock warrant for cash					$ 19,200									$ 232,846	232,846		$ 232,846
Converted into common stock					8,386									101,508			60,568
Common shares issuable in private placement														30,284
Interest expense														$ 188,274
Amortization of debt discount related value attributed beneficial conversion feature																			$ 66,811
Fair value of beneficial conversion feature value																			$ 49,688
Original Warrants [Member] | Note Exchange Agreements [Member]
Number of note warrants														26,681
Dr. Lippa [Member]
Percentage of convertible notes payable							10.00%
Warrants exercise price per share							$ 5.1025
Advances total							$ 52,600
Issuance of fully vested warrant to purchase shares of common stock							10,309
Warrants expiration date							Jan. 29, 2019
Dr. Arnold S. Lippa [Member]
Percentage of convertible notes payable		10.00%
Warrants exercise price per share		$ 4.8500
Advances total		$ 25,000
Issuance of fully vested warrant to purchase shares of common stock		5,155
Warrants expiration date		Sep. 23, 2019
Black-Scholes option-pricing model		$ 22,152															$ 48,245
Dr. James S. Manuso [Member]
Percentage of convertible notes payable			10.00%			10.00%
Warrants exercise price per share			$ 5			$ 6.5000
Advances total			$ 25,000			$ 52,600
Issuance of fully vested warrant to purchase shares of common stock			5,000			8,092
Warrants expiration date			Sep. 22, 2019			Feb. 2, 2019
Black-Scholes option-pricing model			$ 22,151														48,392
Warrants [Member]
Debt instruments maturity date								Sep. 15, 2016
Number of extension warrants issued during period								27,396
Convertible debt original principal amount								$ 579,500
Accrued interest payable								$ 43,758
Percentage of unpaid interest multiplied								50.00%
Dividend price per share								$ 11.3750
Number of original warrants issued during period								50,945
Number of new extensive warrants issued								27,396
Warrants extension, description								The New Warrants and extension of the original Warrants, of approximately 55% for the Notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original Warrants.
Fair value of beneficial conversion feature value								$ 206,689									$ 290,394
New Warrants [Member]
Warrants exercise price per share																				$ 11.3750
New Warrants [Member] | Note Exchange Agreements [Member]
Accrued interest payable														$ 40,983
Secured note payable value														$ 344,483
Number of note warrants														14,259
New Warrants [Member] | Investors [Member]
Debt instruments maturity date																	Sep. 15, 2016
Number of original warrants issued during period																	50,945
Extension of original warrants amount																	$ 277,918
Percentage of warrants description																	The relative fair value method generated respective fair values for each of the Notes, including accrued interest, and the New Warrants and extension of the original Warrants, of approximately 55% for the Notes, including accrued interest, and approximately 45% for the New Warrants and extension of the original Warrants. The 45% value attributed to the New Warrants and extension of the original Warrants of $277,918 was amortized as additional interest expense over the extended term of the Notes.
Fair value of beneficial conversion feature value																	$ 206,689
SY Corporation [Member]
Percentage of convertible notes payable																					12.00%
Interest expense															12,092	12,092	35,881	36,013
SY Corporation [Member] | Won [Member]
Secured note payable value																						$ 465,000,000
SY Corporation [Member] | US Dollars [Member]
Secured note payable value																						$ 400,000
Warrant Purchase Agreement [Member] | Investors [Member]
Debt instruments maturity date													Sep. 15, 2015
Convertible Notes Payable [Member]
Proceeds from issuance of private placements													$ 238,500
Proceeds from issuance of private placements										$ 210,000	$ 85,000	$ 46,000
Terminated short-term convertible notes and warrants									$ 579,500
Number of extension warrants issued during period									50,945
Converted into common stock																			29,768
Number of conversion into common shares attributable to accrued interest																			5,505
Notes Payable [Member]
Accrued interest payable															90,668		$ 90,668		$ 62,616
Converted into common stock																	32,239
Number of conversion into common shares attributable to accrued interest																	7,971
Four Officer Notes [Member]
Interest expense															$ 3,912	$ 2,754	$ 11,608	$ 7,106

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - Notes Payable [Member] - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Principal amount of notes payable	$ 276,000	$ 276,000
Add accrued interest payable	90,667	62,616
Notes payable, gross	$ 366,667	$ 338,616

Notes Payable - Summary of Note

Notes Payable - Summary of Note Payable to Related Party (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total note payable	$ 660,616	$ 594,007
SY Corporation [Member]
Principal amount of note payable	399,774	399,774
Accrued interest payable	255,243	219,362
Foreign currency transaction adjustment	5,599	(25,129)
Total note payable	$ 660,616	$ 594,007

Settlement (Details Narrative)

Settlement (Details Narrative)	Jun. 27, 2017USD ($)$ / sharesshares
Settlements
Number of common stock shares issued, shares | shares	16,453
Number of common stock shares issued, value | $	$ 96,250
Convertible preferred stock, per share | $ / shares	$ 5.85

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Oct. 25, 2017	Oct. 05, 2017	Sep. 28, 2017	Sep. 27, 2017	Aug. 31, 2017	Aug. 29, 2017	Jul. 28, 2017	Jul. 26, 2017	Jun. 30, 2017	Jun. 27, 2017	Mar. 31, 2017	Mar. 28, 2017	Mar. 10, 2017	Jan. 17, 2017	Dec. 31, 2016	Dec. 30, 2016	Dec. 29, 2016	Sep. 12, 2016	Aug. 16, 2016	Mar. 31, 2016	Jan. 08, 2016	Aug. 18, 2015	Aug. 13, 2015	Apr. 17, 2014	Mar. 18, 2014	Aug. 10, 2012	Aug. 16, 2016	Jun. 30, 2016	May 31, 2016	Jun. 30, 2015	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jun. 26, 2017	Apr. 17, 2016	Dec. 31, 2015	Sep. 15, 2015
Preferred stock, shares authorized															5,000,000																5,000,000				5,000,000		5,000,000
Preferred stock, par value															$ 0.001																$ 0.001				$ 0.001		$ 0.001
Preferred stock, shares designated															1,250,000																1,250,000				1,250,000		1,250,000
Preferred stock voting																																			Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”)
Preferred stock shares issuable upon conversion, Per share										$ 5.85
Purchase price per share																										$ 18.2000
Common stock, par value															$ 0.001																$ 0.001				$ 0.001		$ 0.001
Common stock, shares authorized															65,000,000																65,000,000				65,000,000		65,000,000
Amount of common stock split										$ 96,250
Common shares issuable upon conversion										16,453
Warrants exercise price per share															$ 0.035																$ 11.3750				$ 11.3750		$ 0.035
Fair value of market price per share																												$ 7.3775			$ 1.40		$ 4.4900		$ 1.40	$ 4.4900
Stock warrant intrinsic value of exercisable																															$ 144,633		$ 131,329		$ 144,633	$ 131,329
Share granted during period																																			739,000	532,907
Stock option period																																			4 years 99 months 29 days
Stock option intrinsic value of exercisable																																			$ 0
Fair value of common stock																										$ 3,271,402
Sold units for aggregate cash consideration																										179,747
Percentage of common stock issued																										41.00%
Common stock, shares outstanding															2,149,045											443,205					2,586,761				2,586,761		2,149,045
Common stock, shares issued															2,149,045																2,586,761				2,586,761		2,149,045
Issue additional contingent consideration																										56,351
Issuance of contingent shares of common stock																																			6,497
Preferred stock shares issued upon exercise of warrants																															32,239				32,239
Number of Warrants, Outstanding, Exercisable															540,198																985,915		409,914		985,915	409,914	540,198			482,288
Unvested stock options																															$ 197,500				$ 197,500
Number of common stock reserved for issuance																															3,890,131				3,890,131
Number of common stock shares unreserved for future issuance																															58,523,108				58,523,108
General and Administrative Expense [Member]
Stock-based compensation expense																															$ 23,873		$ 837,630		$ 1,150,925	$ 2,821,748
Research and Development Member [Member]
Stock-based compensation expense																															11,700		$ 328,462		606,901	$ 1,129,526
2014 Equity Plan [Member]
Share granted during period																									325,025
2015 Plan [Member]
Charge to operations with stock options																															$ 13,613				$ 13,613
Number of common stock reserved for issuance																															63,236				63,236
2014 Plan [Member]
Number of common stock reserved for issuance																															1,053,201				1,053,201
Consulting Agreement Services [Member] | 2015 Plan [Member]
Option issued to purchase number of common stock																		2,608
Stock option expiration date																		Sep. 12, 2021
Stock option established on grant data price per share																		$ 5.7500
Charge to operations with stock options																		$ 14,384
Pier Merger Agreement [Member]
Issuance of contingent shares of common stock																																					6,497
Series B Convertible Preferred Stock [Member]
Preferred stock conversion into common stock description																																			Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208,375 per share of common stock, which is subject to adjustment under certain circumstances.
Common shares issuable upon conversion																																			11
Series G 1.5% Convertible Preferred Stock [Member]
Preferred stock, shares issued																																							259.7
Preferred stock shares issuable upon conversion																																							242,173
Effective conversion price per share of common stock																																							$ 1.0725
Stock Option [Member]
Fair value of market price per share																																	$ 4.49			$ 4.49
Stock option intrinsic value of exercisable																																				$ 0
Board of Directors [Member]
Preferred stock, shares authorized																			5,000,000								5,000,000
Preferred stock, par value																			$ 0.001								$ 0.001
Preferred stock, shares undesignated															3,505,800																3,505,800				3,505,800		3,505,800
Stockholders' equity, reverse stock split																			325 to 1 reverse stock split
Common stock, par value																			$ 0.001								$ 0.001
Common stock, shares authorized																			65,000,000								65,000,000
Share granted during period																																1,538,461
Board of Directors [Member] | 2015 Stock and Stock Option Plan [Member]
Share granted during period																						769,231
Option issued to purchase number of common stock																														461,538
Stock option period																														10 years
Board of Directors [Member] | January 17, 2017 [Member]
Share granted during period																																			3,038,461
Board of Directors [Member] | 2015 Plan [Member]
Common stock at an exercise price																				$ 7.3775
Stock option expiration date																				Mar. 31, 2021
Charge to operations with stock options																																		$ 844,650		$ 2,686,800
Stock option fair value																				$ 3,774,000
Number of stock shares awarded																												523,075
Stock-based compensation expense																				$ 0
Board of Directors [Member] | 2015 Plan [Member] | March 31, 2016 [Member]
Percentage of vesting appointment rate																				25.00%
Board of Directors [Member] | 2015 Plan [Member] | June 30, 2016 [Member]
Percentage of vesting appointment rate																				25.00%
Board of Directors [Member] | 2015 Plan [Member] | September 30, 2016 [Member]
Percentage of vesting appointment rate																				25.00%
Board of Directors [Member] | Series G 1.5% Convertible Preferred Stock [Member]
Preferred stock, shares designated																			5,000,000								5,000,000
Preferred stock shares issuable upon conversion, Per share																			$ 6.7899								$ 6.7899
Stockholders' equity, reverse stock split																											(325 to 1) reverse stock split								191.068 fractional shares resulting from the reverse stock split
Common stock, par value																			$ 0.001								$ 0.001
Common stock, shares authorized																			70,000,000								70,000,000
Common stock, shares designated																			65,000,000								65,000,000
Common stock designated, par value																			$ 0.001								$ 0.001
Preferred stock designated, par value																			$ 0.001								$ 0.001
Reverse Stock Split [Member] | Series G 1.5% Convertible Preferred Stock [Member]
Amount of common stock split																																			$ 1,298
1st 2016 Unit Offering [Member]
Proceeds from issuance of private placements																					$ 2,500,000														$ 309,985
Purchase of warrants																																			86,006
Number of stock issued for service																																			43,003
Private placement per unit price																					$ 7.2085
Warrants exercise price per share																					$ 7.9300
Percentage of conversion price of common stock																					4.99%
Warrant exercisable date																					Feb. 28, 2021
1st 2016 Unit Offering [Member] | Seven Closing [Member]
Received cash fees																																			$ 3,429
1st 2016 Unit Offering [Member] | Investor Relations Services [Member]
Proceeds from issuance of private placements																												$ 25,350							$ 309,985
Common shares issuable upon conversion																																			3,517
Number of warrants issued during period																																			7,034
2nd 2016 Unit Offering [Member] | Purchase Agreement [Member]
Sale of stock consideration, value																	$ 125,000
2nd 2016 Unit Offering [Member] | Purchase Agreement [Member] | Additional Units to Additional Investors in Second Closing [Member]
Sale of stock consideration, value																$ 60,000
2nd 2016 Unit Offering [Member] | Purchase Agreement [Member] | Final Closing [Member]
Issuance of warrants to acquire common stock															130,284																						130,284
Sale of stock consideration, value															$ 185,000
Warrants exercise price per share															$ 1.562																						$ 1.562
Warrant exercisable date															Dec. 31, 2021
Fair value of closing stock share per price															$ 1.42
Percentage of warrant exercised per unit price															110.00%																						110.00%
Warrants description															The warrants are also subject to a call by the Company at $0.001 per share upon ten (10) days written notice if the Company’s common stock closes at 200% or more of the unit purchase price for any five (5) consecutive trading days.
Warrants purchase additional shares of common stock															130,284																						130,284
2nd 2016 Unit Offering [Member] | Unaffiliated [Member]
Maximum obligated to pay placement agent fees																															$ 13,875				$ 13,875
Maximum percentage of referral source of warrant sold in private placement																															7.50%				7.50%
Paid cash to other professionals for services																																			$ 4,000
2nd 2016 Unit Offering [Member] | Subsequent Financings Aggregate [Member] | December 30, 2017 [Member]
Gross proceeds																																			$ 15,000,000
2nd 2016 Unit Offering [Member]
Purchase price per share																															$ 1.42				$ 1.42
Warrants exercise price per share																$ 2.80	$ 2.85														$ 1.562				$ 1.562
Gross proceeds																$ 185,000	$ 185,000
Percentage of investor beneficially outstanding shares of common stock																															4.99%				4.99%
Percentage of unit purchase price																															200.00%				200.00%
2017 Unit Offering [Member]
Purchase price per share												$ 3.80	$ 4.05
2017 Unit Offering [Member] | Aurora Capital [Member]
Warrants description																																			Common stock warrants valued at $10,374
Cash placement agent fees																																			$ 20,000
Number of warrant shares fee																																			8,000
2017 Unit Offering [Member] | Investors [Member]
Purchase price per share																															$ 2.50				$ 2.50
Common stock, par value																															0.001				0.001
Warrants exercise price per share																															$ 2.75				$ 2.75
Gross proceeds												$ 350,000	$ 350,000
Percentage of investor beneficially outstanding shares of common stock																															4.99%				4.99%
Percentage of unit purchase price																															200.00%				200.00%
2nd 2017 Unit Offering [Member] | Investors [Member]
Purchase price per share	$ .80	$ 1.50	$ 1.40	$ 1.40		$ 1
Warrants exercise price per share	$ 1.10	$ 1.10	$ 1.10	$ 1.10		$ 1.10
Gross proceeds	$ 157,000	$ 157,000	$ 157,000	$ 157,000		$ 157,000
Percentage of investor beneficially outstanding shares of common stock			4.99%	4.99%		4.99%
Percentage of unit purchase price			250.00%	250.00%		250.00%
Gross proceeds from sale of units			$ 126,000	$ 126,000		$ 126,000
Seventeen Individual [Member] | 2015 Plan [Member]
Fair value of market price per share														$ 3.90
Percentage of vesting appointment rate									50.00%		25.00%			25.00%
Stock option expiration date														Jan. 17, 2022
Charge to operations with stock options																																			$ 1,216,378
Stock option fair value														$ 1,464,305
Number of stock shares awarded														395,000
Nine Individual [Member] | 2015 Plan [Member]
Fair value of market price per share																															$ 2				$ 2
Charge to operations with stock options																																			$ 505,875
Stock option fair value									$ 505,875
Number of stock shares awarded									285,000
One Individual [Member] | 2015 Plan [Member]
Fair value of market price per share							$ 1.35																															$ 2
Percentage of vesting appointment rate								25.00%																											25.00%
Stock option fair value							$ 39,807	$ 27,225
Number of stock shares awarded								25,000
One Individual [Member] | 2015 Plan [Member] | December 31, 2017 [Member]
Percentage of vesting appointment rate																																			50.00%
Two Individual [Member] | 2015 Plan [Member]
Stock option vested percentage, description							With respect to one individual, the 9,000 options vested 33 1/3% upon grant, 33 1/3 % on August 31, 2017 and 33 1/3% on September 30, 2017 such that all options vested by September 30, 2017.
Number of stock shares awarded							34,000
Other Individual [Member] | 2015 Plan [Member]
Percentage of vesting appointment rate					20.00%																														20.00%
Charge to operations with stock options																															$ 22,257				$ 22,257
Number of shares vested					25,000																														25,000
Other Individual [Member] | 2015 Plan [Member] | October 31, 2017 [Member]
Percentage of vesting appointment rate																																			20.00%
Number of shares vested																																			25,000
Other Individual [Member] | 2015 Plan [Member] | November 31, 2017 [Member]
Percentage of vesting appointment rate																																			20.00%
Number of shares vested																																			25,000
Other Individual [Member] | 2015 Plan [Member] | December 30, 2017 [Member]
Percentage of vesting appointment rate																																			20.00%
Number of shares vested																																			25,000
Officer And Director [Member]
Share granted during period																										22,651
Stock options exercise price																										$ 19.5000
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized															37,500																37,500				37,500		37,500
Preferred stock, par value															$ 0.001																$ 0.001				$ 0.001		$ 0.001
Preferred stock, shares designated															37,500																37,500				37,500		37,500
Preferred stock, shares issued															11																11				11		11
Preferred stock shares issuable upon conversion, Per share															$ 0.00030																$ 0.00030				$ 0.00030		$ 0.00030
Preferred stock shares issuable upon conversion															11																11				11		11
Preferred stock redemption amount															$ 25,001																$ 25,001				$ 25,001		$ 25,001
Redeemed preferred stock price per share															$ 0.6667																$ 0.6667				$ 0.6667		$ 0.6667
Preferred stock shares issued upon exercise of warrants																															548,198				548,198
Number of Warrants, Outstanding, Exercisable																															1,702,749				1,702,749
Series B Convertible Preferred Stock [Member] | May Ninteen Ninty One Private Placement [Member]
Preferred stock, shares issued															37,500																37,500				37,500		37,500
Series B Convertible Preferred Stock [Member] | Stock Option [Member]
Conversion of stock																																				2,046,749
Series B Convertible Preferred Stock [Member] | Warrant [Member]
Conversion of stock																																				688,198
Series A Junior Participating Preferred Stock [Member]
Preferred stock, shares designated															205,000																205,000				205,000		205,000
Series G 1.5% Convertible Preferred Stock [Member]
Preferred stock, shares designated															1,700																1,700				1,700		1,700
Series G 1.5% Convertible Preferred Stock [Member] | Securities Purchase Agreements [Member]
Number of preferred stock shares sold																								928.50
Purchase price per share																								$ 1,000	$ 1,000
Sold units for aggregate cash consideration																								175.28
Series G 1.5% Convertible Preferred Stock [Member] | Securities Purchase Agreements [Member] | Private Placement [Member]
Number of preferred stock shares sold																									928.50
Aggregate purchase amount of shares																								$ 928,500	$ 928,500
Sold units for aggregate cash consideration																								928.5
Existing Warrants [Member] | Unit Exchange Agreements [Member]
Issuance of warrants to acquire common stock																													217,187
Warrants exercised cashless basis gross																													$ 529,394
Common stock at an exercise price																													$ 4.8750
Warrants expiration date																													Sep. 30, 2020
Warrant Holders [Member] | Unit Exchange Agreements [Member]
Common shares issuable upon conversion																													108,594
Sale of stock consideration, value																													$ 728,859
Common stock at an exercise price																													$ 6.7275
New Warrants [Member]
Warrants exercise price per share																																									$ 11.3750
New Warrants [Member] | Unit Exchange Agreements [Member]
Issuance of warrants to acquire common stock																													108,594
Warrants expiration date																																			Sep. 30, 2020
Warrants exercise price per share																															$ 4.8750				$ 4.8750
Warrant [Member]
Number of warrants issued during period																							27,396
Additional paid in capital warrants																																			$ 27,648
Number of Warrants, Outstanding, Exercisable																															985,915		409,914		985,915	409,914

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Warrant Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	540,198	482,288
Number of Warrants, Exercisable, Beginning balance	540,198	482,288
Number of Warrants, Issued	445,717	(72,374)
Number of Warrants, Outstanding, Ending balance	985,915	409,914
Number of Warrants, Exercisable, Ending balance	985,915	409,914
Weighted Average Exercise Price, Outstanding, Beginning	$ 4.84842	$ 7.10125
Weighted Average Exercise Price, Exercisable Beginning	4.84842	7.10125
Weighted Average Exercise Price, Issued	1.36478	(1.03629)
Weighted Average Exercise Price, Outstanding, Ending	3.27352	5.89296
Weighted Average Exercise Price, Exercisable, Ending	$ 3.27352	$ 5.89296
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years)	4 years 908 months 2 days	3 years 10 months 3 days
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years)	4 years 908 months 2 days	3 years 10 months 3 days

Stockholders' Deficiency - Sc34

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Warrants, Outstanding (Shares)	985,915	409,914	540,198	482,288
Warrants, Exercisable (Shares)	985,915	409,914	540,198	482,288
Warrants [Member]
Warrants, Outstanding (Shares)	985,915	409,914
Warrants, Exercisable (Shares)	985,915	409,914
Exercise Price Range One [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.2870	$ 1.2870
Warrants, Outstanding (Shares)	41,002	41,002
Warrants, Exercisable (Shares)	41,002	41,002
Warrants, Expiration Date	Apr. 17, 2019	Apr. 17, 2019
Exercise Price Range Two [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.5620	$ 4.8500
Warrants, Outstanding (Shares)	0	5,155
Warrants, Exercisable (Shares)	0	5,155
Warrants, Expiration Date	Dec. 31, 2021	Sep. 23, 2019
Exercise Price Range Three [Member] | Warrants [Member]
Warrants, Exercise Price	$ 4.8500	$ 4.8750
Warrants, Outstanding (Shares)	5,155	108,594
Warrants, Exercisable (Shares)	5,155	108,594
Warrants, Expiration Date	Sep. 23, 2019	Sep. 30, 2020
Exercise Price Range Four [Member] | Warrants [Member]
Warrants, Exercise Price	$ 4.8750	$ 5
Warrants, Outstanding (Shares)	108,594	5,000
Warrants, Exercisable (Shares)	108,594	5,000
Warrants, Expiration Date	Sep. 30, 2020	Sep. 22, 2019
Exercise Price Range Five [Member] | Warrants [Member]
Warrants, Exercise Price	$ 5	$ 5.1025
Warrants, Outstanding (Shares)	5,000	10,309
Warrants, Exercisable (Shares)	5,000	10,309
Warrants, Expiration Date	Sep. 22, 2019	Jan. 29, 2019
Exercise Price Range Six [Member] | Warrants [Member]
Warrants, Exercise Price	$ 5.1025	$ 6.5000
Warrants, Outstanding (Shares)	10,309	8,092
Warrants, Exercisable (Shares)	10,309	8,092
Warrants, Expiration Date	Jan. 29, 2019	Feb. 4, 2019
Exercise Price Range Seven [Member] | Warrants [Member]
Warrants, Exercise Price	$ 6.5000	$ 6.8348
Warrants, Outstanding (Shares)	8,092	145,758
Warrants, Exercisable (Shares)	8,092	145,758
Warrants, Expiration Date	Feb. 4, 2019	Sep. 30, 2020
Exercise Price Range Eight [Member] | Warrants [Member]
Warrants, Exercise Price	$ 6.8348	$ 7.9300
Warrants, Outstanding (Shares)	145,758	86,004
Warrants, Exercisable (Shares)	145,758	86,004
Warrants, Expiration Date	Sep. 30, 2020	Feb. 28, 2021
Exercise Price Range Nine [Member] | Warrants [Member]
Warrants, Exercise Price	$ 7.9300
Warrants, Outstanding (Shares)	86,005
Warrants, Exercisable (Shares)	86,005
Warrants, Expiration Date	Feb. 28, 2021
Exercise Price Range Ten [Member] | Warrants [Member]
Warrants, Exercise Price	$ 2.7500
Warrants, Outstanding (Shares)	108,000
Warrants, Exercisable (Shares)	108,000
Warrants, Expiration Date	Dec. 31, 2021
Exercise Price Range Eleven [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.1000
Warrants, Outstanding (Shares)	468,000
Warrants, Exercisable (Shares)	468,000
Warrants, Expiration Date	Sep. 29, 2022

Stockholders' Deficiency - Sc35

Stockholders' Deficiency - Schedule of Stock Options Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Equity [Abstract]
Number of Options, Outstanding, Beginning balance	1,307,749	774,842
Number of Options, Exercisable, Beginning balance	1,307,749	519,662
Number of Options, Granted	739,000	532,907
Number of Options, Outstanding, Ending balance	2,046,749	1,307,749
Number of Options, Exercisable, Ending balance	2,019,249	1,177,364
Weighted Average Exercise Price, Outstanding, Beginning	$ 7.6515	$ 7.8325
Weighted Average Exercise Price, Exercisable, Beginning	7.6515	8.5150
Weighted Average Exercise Price, Granted		7.3305
Weighted Average Exercise Price, Outstanding, Ending	6.0125	7.6241
Weighted Average Exercise Price, Exercisable, Ending	$ 6.0125	$ 7.6515
Options Outstanding, Weighted Average Remaining Contractual Life (in Years)	4 years 6 months 14 days	5 years 6 months 21 days
Options Exercisable, Weighted Average Remaining Contractual Life (in Years)	4 years 6 months 14 days	5 years 8 months 5 days

Stockholders' Deficiency - Sc36

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Options Outstanding (Shares)	2,046,749	1,307,749	1,307,749	1,307,749	774,842
Options Exercisable (Shares)	2,019,249	1,177,364	1,307,749	1,177,364	519,662
Stock Option One [Member]
Options Exercise Price	$ 1.3500	$ 4.500
Options Outstanding (Shares)	34,000	7,222
Options Exercisable (Shares)	19,000	7,222
Options, Expiration Date	Jul. 28, 2022	Sep. 2, 2021
Stock Option Two [Member]
Options Exercise Price	$ 2	$ 5.7500
Options Outstanding (Shares)	285,000	2,608
Options Exercisable (Shares)	285,000	2,608
Options, Expiration Date	Jun. 30, 2022	Sep. 12, 2021
Stock Option Three [Member]
Options Exercise Price	$ 2	$ 5.6875
Options Outstanding (Shares)	25,000	89,686
Options Exercisable (Shares)	25,000	89,686
Options, Expiration Date	Jul. 26, 2022	Jun. 30, 2020
Stock Option Four [Member]
Options Exercise Price	$ 3.9000	$ 6.4025
Options Outstanding (Shares)	395,000	27,692
Options Exercisable (Shares)	395,000	27,692
Options, Expiration Date	Jan. 17, 2022	Aug. 18, 2020
Stock Option Five [Member]
Options Exercise Price	$ 4.5000	$ 6.4025
Options Outstanding (Shares)	7,222	129,231
Options Exercisable (Shares)	7,222	129,231
Options, Expiration Date	Sep. 2, 2021	Aug. 18, 2022
Stock Option Six [Member]
Options Exercise Price	$ 5.6875	$ 6.4025
Options Outstanding (Shares)	89,686	261,789
Options Exercisable (Shares)	89,686	261,789
Options, Expiration Date	Jun. 30, 2020	Aug. 18, 2025
Stock Option Seven [Member]
Options Exercise Price	$ 5.7500	$ 6.8250
Options Outstanding (Shares)	2,608	8,791
Options Exercisable (Shares)	2,608	8,791
Options, Expiration Date	Sep. 12, 2021	Dec. 11, 2020
Stock Option Eight [Member]
Options Exercise Price	$ 6.4025	$ 7.3775
Options Outstanding (Shares)	27,692	523,077
Options Exercisable (Shares)	27,692	392,692
Options, Expiration Date	Aug. 18, 2020	Mar. 31, 2021
Stock Option Nine [Member]
Options Exercise Price	$ 6.4025	$ 8.12500
Options Outstanding (Shares)	129,231	169,231
Options Exercisable (Shares)	129,231	169,231
Options, Expiration Date	Aug. 18, 2022	Jun. 30, 2022
Stock Option Ten [Member]
Options Exercise Price	$ 6.4025	$ 13
Options Outstanding (Shares)	261,789	7,385
Options Exercisable (Shares)	261,789	7,385
Options, Expiration Date	Aug. 18, 2025	Mar. 13, 2019
Stock Option Eleven [Member]
Options Exercise Price	$ 6.8250	$ 13
Options Outstanding (Shares)	8,791	3,846
Options Exercisable (Shares)	8,791	3,846
Options, Expiration Date	Dec. 11, 2020	Apr. 14, 2019
Stock Option Twelve[Member]
Options Exercise Price	$ 7.3775	$ 13.9750
Options Outstanding (Shares)	523,077	3,385
Options Exercisable (Shares)	523,077	3,385
Options, Expiration Date	Mar. 31, 2021	Mar. 14, 2024
Stock Option Thirteen [Member]
Options Exercise Price	$ 8.1250	$ 15.4700
Options Outstanding (Shares)	169,231	7,755
Options Exercisable (Shares)	169,231	7,755
Options, Expiration Date	Jun. 30, 2022	Apr. 8, 2020
Stock Option Fourteen [Member]
Options Exercise Price	$ 13	$ 15.9250
Options Outstanding (Shares)	7,385	2,462
Options Exercisable (Shares)	7,385	2,462
Options, Expiration Date	Mar. 13, 2019	Feb. 28, 2024
Stock Option Fifteen [Member]
Options Exercise Price	$ 13	$ 16.2500
Options Outstanding (Shares)	3,846	46,154
Options Exercisable (Shares)	3,846	46,154
Options, Expiration Date	Apr. 14, 2019	Jul. 17, 2019
Stock Option Sixteen [Member]
Options Exercise Price	$ 13.9750	$ 16.6400
Options Outstanding (Shares)	3,385	1,538
Options Exercisable (Shares)	3,385	1,538
Options, Expiration Date	Mar. 14, 2024	Jan. 29, 2020
Stock Option Seventeen [Member]
Options Exercise Price	$ 15.4700	$ 19.5000
Options Outstanding (Shares)	7,755	9,487
Options Exercisable (Shares)	7,755	9,487
Options, Expiration Date	Apr. 8, 2020	Jul. 17, 2022
Stock Option Eighteen [Member]
Options Exercise Price	$ 15.9250	$ 19.500
Options Outstanding (Shares)	2,462	6,410
Options Exercisable (Shares)	2,462	6,410
Options, Expiration Date	Feb. 28, 2024	Aug. 10, 2022
Stock Option Nineteen [Member]
Options Exercise Price	$ 16.0500
Options Outstanding (Shares)	46,154
Options Exercisable (Shares)	46,154
Options, Expiration Date	Jul. 17, 2019
Stock Option Twenty [Member]
Options Exercise Price	$ 16.6400
Options Outstanding (Shares)	1,538
Options Exercisable (Shares)	1,538
Options, Expiration Date	Jan. 29, 2020
Stock Option Twenty One [Member]
Options Exercise Price	$ 19.5000
Options Outstanding (Shares)	9,487
Options Exercisable (Shares)	9,487
Options, Expiration Date	Jul. 17, 2022
Stock Option Twenty Two [Member]
Options Exercise Price	$ 19.5000
Options Outstanding (Shares)	6,410
Options Exercisable (Shares)	6,410
Options, Expiration Date	Aug. 10, 2022

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 28, 2017	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2017	Mar. 31, 2013
2017 Unit Offering [Member]
Cash placement agent fees	$ 20,000
Number of warrant shares fee	8,000
Common stock warrant for cash				$ 27,648
Employment Agreements [Member] | Tranche One [Member]
Cash bonuses		$ 15,000
Employment Agreements [Member] | Tranche Two [Member]
Cash bonuses		15,000
Employment Agreements [Member] | Tranche Three [Member]
Cash bonuses		30,000
Excess of financing cost		200,000
Board of Directors [Member]
Cash bonuses			$ 215,000
Executive Officers [Member]
Cash bonuses			195,000
Independent [Member]
Cash bonuses			20,000
Jeff E. Margolis [Member]
Cash bonuses			60,000
Cash compensation			10,000
Robert N Weingarten [Member]
Cash bonuses			60,000
Cash compensation			10,000
James E. Sapirstein [Member]
Cash bonuses			10,000
Cash compensation			5,000
Kathryn MacFarlane [Member]
Cash bonuses			10,000
Cash compensation			5,000
Kathryn MacFarlane [Member] | Employment Agreements [Member]
Cash bonuses		60,000
Excess of financing cost		100,000
Kathryn MacFarlane [Member] | Employment Agreements [Member] | Additional [Member]
Excess of financing cost		250,000
Kathryn MacFarlane [Member] | Employment Agreements [Member] | Minimum [Member]
Cash bonuses		$ 15,000
Aurora Capital LLC [Member]
Reimbursement for legal fees accrued					$ 85,000
Dr. Arnold S. Lippa [Member]
Cash bonuses			75,000
Cash compensation			$ 12,500

Commitments and Contingencies38

Commitments and Contingencies (Details Narrative)	Jul. 26, 2017$ / shares	Jan. 18, 2017USD ($)	Oct. 26, 2016USD ($)	Jul. 28, 2016USD ($)	Jul. 21, 2016USD ($)	Jan. 12, 2016USD ($)	Jan. 12, 2016CAD	Oct. 30, 2015USD ($)	Aug. 18, 2015USD ($)shares	Aug. 18, 2015USD ($)shares	Aug. 18, 2015USD ($)shares	Jan. 27, 2015USD ($)	Nov. 11, 2014USD ($)	Oct. 15, 2014USD ($)	Jun. 27, 2014USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2011USD ($)	Sep. 30, 2010USD ($)	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)shares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)shares	Jun. 30, 2016shares	Dec. 31, 2015shares
Arbitrator awarded amount		$ 146,082
Attorneys' fees and costs		$ 47,930
Unpaid investment banking services					$ 225,000
Stock options to purchase | shares																			2,046,749	1,307,749	2,046,749	1,307,749	1,307,749	1,307,749	774,842
Number of options granted | shares																					739,000	532,907
Option granted exercise price | $ / shares																						$ 7.3305
Minimum annual royalty payment amount																					$ 70,000
Minimum amount to be spent to advance the ampakine compounds																					250,000
Clinical study and research total cost												$ 50,579
Estimated cost expected								$ 558,268
Research and development expenses																			$ 236,856	$ 899,543	1,298,866	$ 2,743,599
Principal cash obligations and commitments																			1,518,800		1,518,800
Mr. Manuso [Member]
Cash compensation expense									$ 375,000
Percentage of annual bonus from base salary									50.00%
Stock options to purchase | shares									261,789	261,789	261,789
Health plan for employees expense									$ 1,200
Maximum health coverage amount per month									$ 1,000
Dr. Arnold S. Lippa [Member]
Cash compensation expense											$ 300,000
Percentage of annual bonus from base salary											50.00%
Stock options to purchase | shares									30,769	30,769	30,769
Health plan for employees expense											$ 1,200
Maximum health coverage amount per month											1,000
Bonus paid																$ 12,500
President And Chief Executive Officer [Member]
Cash compensation expense																					94,758	94,758
Mr Margolis And Mr Weingarten [Member]
Cash compensation expense										$ 151,612	$ 195,000								0	54,150	28,524	162,450
Stock options to purchase | shares									30,769	30,769	30,769
Health plan for employees expense											$ 1,200
Maximum health coverage amount per month											1,000
Mr Margolis And Mr Weingarten [Member] | Minimum [Member]
Bonuses									$ 65,000	$ 65,000	65,000
Mr Margolis And Mr Weingarten [Member] | Maximum [Member]
Bonuses									$ 125,000	125,000	$ 125,000
Mr Margolis [Member]
Cash compensation expense										$ 75,806									80,400	54,150	54,150	162,450
Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten [Member]
Net proceeds from offering cost																					2,000,000
Biovail [Member]
Reimbursement related expenses																		$ 15,000,000
Payments for future potential																	$ 15,150,000
Additional payments received upto																	$ 15,000,000
DNA Healthlink, Inc [Member] | Richard Purcell [Member]
Cash fee														$ 12,500
Cash compensation expense																			37,500	37,500	112,500	112,500
Employment and Consulting Agreements [Member]
Cash compensation expense																			103,650	310,950	103,650	317,700
University Of Illinois 2014 Exclusive License Agreement [Member]
License agreement effective date															Sep. 18, 2014
License fee															$ 25,000
Outstanding patent costs															$ 15,840
Charge to operations with stock options																			25,000	25,000	75,000	75,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Two Human Clinical Study [Member]
Payment for sale of product																					75,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Closing Of First Patient Product Phase Three Human Clinical Trial [Member]
Payment for sale of product																					350,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]
Payment for sale of product																					500,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months After First Commercial Sale Of Product Member [Member]
Payment for sale of product																					1,000,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Research and Development Expenses [Member]
Minimum annual royalty payment amount																					250,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Minimum [Member]
Minimum annual royalty payment amount																					100,000	$ 100,000
Percentage of royalty on net sale																						4.00%
Percentage of payment on sub licensee revenue																						12.50%
University Of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Sale Of Product [Member]
Minimum annual royalty payment amount																							$ 150,000
University Of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Commercial Sale Of Product [Member]
Minimum annual royalty payment amount																							$ 200,000
Neuroscience and Mental Health Institute at University of Alberta [Member]
Research grants award amount						$ 112,000
Additional cost budgeted under research grant						65,000
Funding cash installments						16,000
Payments to patent costs						15,000
Underwrite additional budgeted costs						$ 15,000
Accounts payable																			$ 16,207		$ 16,207
Foreign conversion exchange rate						0.77	0.77												0.80		0.80
Research and development expenses																			$ 0	193,119	$ 36,420	$ 602,642
Neuroscience and Mental Health Institute at University of Alberta [Member] | CAD [Member]
Research grants award amount | CAD							CAD 146,000
Additional cost budgeted under research grant | CAD							85,000
Funding cash installments | CAD							21,000
Payments to patent costs | CAD							20,000
Underwrite additional budgeted costs | CAD							CAD 20,000
Foreign conversion exchange rate						1	1												1		1
Duke University Clinical Trial Agreement [Member]
Post-clinical trial costs				$ 120,059
Amount payable				$ 678,327
Budgeted cost			$ 35,958
Former Director [Member]
Unpaid consulting compensation													$ 24,000
Dr. Arnold S. Lippa [Member]
Cash compensation expense																			$ 93,900	$ 254,700	$ 80,400	$ 169,800
Jeff Margolis [Member] | Employment Agreements [Member]
Number of options granted | shares																					25,000
Percentage of vesting appointment rate	25.00%
Option granted exercise price | $ / shares	$ 2
Jeff Margolis [Member] | Employment Agreements [Member] | September 30, 2017 [Member]
Percentage of vesting appointment rate	25.00%
Jeff Margolis [Member] | Employment Agreements [Member] | December 31, 2017 [Member]
Percentage of vesting appointment rate	50.00%
Jeff Margolis [Member] | Employment Agreements [Member] | Tranche One [Member]
Bonus paid																					$ 15,000
Related party debt																					100,000
Jeff Margolis [Member] | Employment Agreements [Member] | Tranche Two [Member]
Bonus paid																					15,000
Related party debt																					200,000
Jeff Margolis [Member] | Employment Agreements [Member] | Tranche Three [Member]
Bonus paid																					30,000
Related party debt																					250,000
Jeff Margolis [Member] | Employment Agreements [Member] | Minimum [Member]
Cash compensation expense																					195,000
Jeff Margolis [Member] | Employment Agreements [Member] | Maximum [Member]
Cash compensation expense																					$ 300,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details)	Sep. 30, 2017USD ($)
2,017	$ 298,450
2,018	920,350
2,019	100,000
2,020	100,000
2,021	100,000
Total	1,518,800
Research and Development Contracts [Member]
2,017
2,018
2,019
2,020
2,021
Total
Clinical Trial Agreements [Member]
2,017
2,018
2,019
2,020
2,021
Total
License Agreements [Member]
2,017	25,000
2,018	100,000
2,019	100,000
2,020	100,000
2,021	100,000
Total	425,000
Employment and Consulting Agreements [Member]
2,017	273,450	[1]
2,018	820,350	[1]
2,019		[1]
2,020		[1]
2,021		[1]
Total	$ 1,093,800	[1]
[1]	The payment of such amounts has been deferred indefinitely, as described above at "Employment Agreements".

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 25, 2017	Oct. 05, 2017	Oct. 02, 2017	Jun. 27, 2017
Stock issued during period, value				$ 96,250
Number of common stock shares issued, shares				16,453
Subsequent Event [Member] | Common Stock One[Member]
Warrant to purchase common stock			20,000
Subsequent Event [Member] | Common StockTwo [Member]
Warrant to purchase common stock			60,000
Subsequent Event [Member] | 2017 Unit Offering [Member]
Stock issued during period, value	$ 31,000	$ 31,000
Number of common stock shares issued, shares	31,000	31,000
Warrant to purchase common stock	31,000	31,000
Subsequent Event [Member] | Unit Offering Exchange [Member]
Cancellation of common stock			40,000